HealthLynked (HLYK) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 14, 2022
Document Information Line Items
Entity Registrant Name	HealthLynked Corp
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		254,382,625
Amendment Flag	false
Entity Central Index Key	0001680139
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-55768
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	47-1634127
Entity Address, Address Line One	1265 Creekside Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	Naples
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34108
City Area Code	(800)
Local Phone Number	928-7144
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current Assets
Cash	$ 158,160	$ 3,291,646
Accounts receivable, net of allowance for doubtful accounts of $-0- and $13,972 as of September 30, 2022 and December 31, 2021, respectively	63,855	86,287
Inventory	188,546	134,930
Prepaid expenses and other	94,968	137,630
Total Current Assets	505,529	3,650,493
Property, plant and equipment, net of accumulated depreciation of $368,985 and $283,512 as of September 30, 2022 and December 31, 2021, respectively	441,332	350,482
Intangible assets, net of accumulated amortization of $1,410,250 and $873,417 as of September 30, 2022 and December 31, 2021, respectively	4,343,288	4,880,121
Goodwill	1,468,063	1,148,105
Right of use lease assets	636,267	526,730
Deferred equity compensation and deposits	84,091	138,625
Total Assets	7,478,570	10,694,556
Current Liabilities
Accounts payable and accrued expenses	1,194,293	790,843
Contract liabilities	65,252	72,838
Lease liability, current portion	378,759	288,966
Due to related party, current portion	300,600	300,600
Notes payable, current portion, net of unamortized original issue discount of $20,879 and $-0- as of September 30, 2022 and December 31, 2021	397,869
Liability-classified equity instruments, current portion	30,625	61,250
Contingent acquisition consideration, current portion	128,074	403,466
Total Current Liabilities	2,495,472	1,917,963
Long-Term Liabilities
Government notes payable, long term portion	450,000	450,000
Liability-classified equity instruments, long term portion	52,500	101,250
Contingent acquisition consideration, long term portion	184,659	782,224
Lease liability, long term portion	259,845	239,225
Total Liabilities	3,442,476	3,490,662
Shareholders’ Equity
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 247,857,625 and 237,893,473 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	24,786	23,789
Series B convertible preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 2,750,000 and 2,750,000 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	2,750	2,750
Common stock issuable, $0.0001 par value; 1,329,469 and 719,366 shares as of September 30, 2022 and December 31, 2021, respectively	345,345	282,347
Additional paid-in capital	40,410,147	39,100,197
Accumulated deficit	(36,746,934)	(32,205,189)
Total Shareholders’ Equity	4,036,094	7,203,894
Total Liabilities and Shareholders’ Equity	$ 7,478,570	$ 10,694,556

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Accounts receivable, net of allowance for doubtful accounts (in Dollars)	$ 0	$ 13,972
Property, plant and equipment, net of accumulated depreciation (in Dollars)	368,985	283,512
Intangible assets, net of accumulated amortization (in Dollars)	1,410,250	873,417
Notes payable, current portion, net of unamortized original issue discount (in Dollars)	$ 20,879	$ 0
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	247,857,625	237,893,473
Common stock, shares outstanding	247,857,625	237,893,473
Common stock issuable, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock issuable, shares	1,329,469	719,366
Series B Convertible Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	2,750,000	2,750,000
Preferred stock, shares outstanding	2,750,000	2,750,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue
Patient service revenue, net	$ 1,262,253	$ 1,394,356	$ 4,069,714	$ 4,379,282
Medicare shared savings revenue		2,419,312		2,419,312
Subscription, consulting and event revenue	89,977	69,595	260,491	229,114
Product revenue	95,449	161,456	372,877	512,325
Total revenue	1,447,679	4,044,719	4,703,082	7,540,033
Operating Expenses and Costs
Practice salaries and benefits	810,058	739,024	2,344,529	2,305,993
Other practice operating expenses	695,300	549,086	1,897,070	1,790,874
Medicare shared savings expenses	337,533	1,748,585	802,411	2,157,555
Cost of product revenue	87,775	145,432	419,129	474,026
Selling, general and administrative expenses	1,088,133	1,147,591	3,678,784	3,661,206
Depreciation and amortization	209,504	205,311	622,306	623,438
Total Operating Expenses and Costs	3,228,303	4,535,029	9,764,229	11,013,092
Loss from operations	(1,780,624)	(490,310)	(5,061,147)	(3,473,059)
Other Income (Expenses)
Gain (loss) on extinguishment of debt				(4,957,168)
Change in fair value of debt				(19,246)
Financing cost	(110,000)		(110,000)
Amortization of original issue discounts on notes payable	(21,020)		(21,020)
Change in fair value of contingent acquisition consideration	133,483	126,411	665,573	(234,678)
Interest (expense) income	(5,640)	(4,118)	(15,151)	(13,083)
Total other income (expenses)	(3,177)	122,293	519,402	(5,224,175)
Net loss before provision for income taxes	(1,783,801)	(368,017)	(4,541,745)	(8,697,234)
Provision for income taxes
Net loss	(1,783,801)	(368,017)	(4,541,745)	(8,697,234)
Deemed dividend - amortization of beneficial conversion feature	(88,393)	(88,393)	(265,179)	(265,179)
Net loss to common shareholders	$ (1,872,194)	$ (456,410)	$ (4,806,924)	$ (8,962,413)
Net loss per share to common shareholders, basic and diluted:
Basic (in Dollars per share)	$ (0.01)	$ 0	$ (0.02)	$ (0.04)
Fully diluted (in Dollars per share)	$ (0.01)	$ 0	$ (0.02)	$ (0.04)
Weighted average number of common shares:
Basic (in Shares)	243,355,562	232,203,244	240,006,507	224,658,709
Fully diluted (in Shares)	243,355,562	232,203,244	240,006,507	224,658,709

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Shareholders’ Equity (Deficit) (Unaudited) - USD ($)	Common Stock	Preferred Stock	Common Stock Issuable	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2020	$ 18,797	$ 2,750	$ 262,273	$ 22,851,098	$ (21,784,910)	$ 1,350,008
Balance (in Shares) at Dec. 31, 2020	187,967,881	2,750,000
Sales of common stock	$ 1,479			2,981,367		2,982,846
Sales of common stock (in Shares)	14,793,864
Fair value of warrants allocated to proceeds of common stock				1,406,515		1,406,515
Conversion of convertible notes payable to common stock	$ 1,354			4,060,194		4,061,548
Conversion of convertible notes payable to common stock (in Shares)	13,538,494
Fair value of warrants issued in connection with conversion and retirement of convertible notes payable				3,201,138		3,201,138
Fair value of warrants issued for professional services				32,426		32,426
Consultant and director fees payable with common shares and warrants	$ 48		114,500	122,781		237,329
Consultant and director fees payable with common shares and warrants (in Shares)	475,000
Shares and options issued pursuant to employee equity incentive plan	$ 24		(14,956)	52,337		37,405
Shares and options issued pursuant to employee equity incentive plan (in Shares)	240,310
Exercise of stock warrants	$ 905		62,500	613,316		676,721
Exercise of stock warrants (in Shares)	9,047,332
Exercise of stock options	$ 1			3,149		3,150
Exercise of stock options (in Shares)	12,500
Net loss					(7,823,453)	(7,823,453)
Balance at Mar. 31, 2021	$ 22,608	$ 2,750	424,317	35,324,321	(29,608,363)	6,165,633
Balance (in Shares) at Mar. 31, 2021	226,075,381	2,750,000
Balance at Dec. 31, 2020	$ 18,797	$ 2,750	262,273	22,851,098	(21,784,910)	1,350,008
Balance (in Shares) at Dec. 31, 2020	187,967,881	2,750,000
Net loss						(8,697,234)
Balance at Sep. 30, 2021	$ 23,570	$ 2,750	728,368	38,497,916	(30,482,144)	8,770,460
Balance (in Shares) at Sep. 30, 2021	235,703,829	2,750,000
Balance at Mar. 31, 2021	$ 22,608	$ 2,750	424,317	35,324,321	(29,608,363)	6,165,633
Balance (in Shares) at Mar. 31, 2021	226,075,381	2,750,000
Sales of common stock	$ 37			177,642		177,679
Sales of common stock (in Shares)	374,177
Fair value of warrants allocated to proceeds of common stock				82,320		82,320
Fair value of warrants issued for professional services				3,603		3,603
Consultant and director fees payable with common shares and warrants	$ 9		68,807	17,990		86,806
Consultant and director fees payable with common shares and warrants (in Shares)	93,492
Shares and options issued pursuant to employee equity incentive plan	$ 88		(147,791)	211,358		63,655
Shares and options issued pursuant to employee equity incentive plan (in Shares)	875,047
Exercise of stock warrants	$ 123		62,500	152,378		215,001
Exercise of stock warrants (in Shares)	1,225,000
Exercise of stock options	$ 13			13,287		13,300
Exercise of stock options (in Shares)	133,000
Net loss					(505,764)	(505,764)
Balance at Jun. 30, 2021	$ 22,878	$ 2,750	407,833	35,982,899	(30,114,127)	6,302,233
Balance (in Shares) at Jun. 30, 2021	228,776,097	2,750,000
Sales of common stock	$ 470			1,608,874		1,609,344
Sales of common stock (in Shares)	4,703,704
Fair value of warrants allocated to proceeds of common stock				690,577		690,577
Fair value of warrants issued for professional services				3,603		3,603
Contingent acquisition consideration issuable			366,300			366,300
Consultant and director fees payable with common shares and warrants	$ 1		84,785	4,942		89,728
Consultant and director fees payable with common shares and warrants (in Shares)	8,750
Shares and options issued pursuant to employee equity incentive plan	$ 37		(5,550)	25,955		20,442
Shares and options issued pursuant to employee equity incentive plan (in Shares)	375,000
Exercise of stock warrants	$ 184		(125,000)	181,066		56,250
Exercise of stock warrants (in Shares)	1,840,278
Net loss					(368,017)	(368,017)
Balance at Sep. 30, 2021	$ 23,570	$ 2,750	728,368	38,497,916	(30,482,144)	8,770,460
Balance (in Shares) at Sep. 30, 2021	235,703,829	2,750,000
Balance at Dec. 31, 2021	$ 23,789	$ 2,750	282,347	39,100,197	(32,205,189)	7,203,894
Balance (in Shares) at Dec. 31, 2021	237,893,473	2,750,000
Consultant and director fees payable with common shares and warrants	$ 1		73,470	8,044		81,515
Consultant and director fees payable with common shares and warrants (in Shares)	5,250
Shares and options issued to employees	$ 13		(37,777)	64,547		26,783
Shares and options issued to employees (in Shares)	133,000
Exercise of stock options
Exercise of stock options (in Shares)	1,394
Net loss					(1,168,123)	(1,168,123)
Balance at Mar. 31, 2022	$ 23,803	$ 2,750	318,040	39,172,788	(33,373,312)	6,144,069
Balance (in Shares) at Mar. 31, 2022	238,033,117	2,750,000
Balance at Dec. 31, 2021	$ 23,789	$ 2,750	282,347	39,100,197	(32,205,189)	7,203,894
Balance (in Shares) at Dec. 31, 2021	237,893,473	2,750,000
Net loss						(4,541,745)
Balance at Sep. 30, 2022	$ 24,786	$ 2,750	345,345	40,410,147	(36,746,934)	4,036,094
Balance (in Shares) at Sep. 30, 2022	247,857,625	2,750,000
Balance at Mar. 31, 2022	$ 23,803	$ 2,750	318,040	39,172,788	(33,373,312)	6,144,069
Balance (in Shares) at Mar. 31, 2022	238,033,117	2,750,000
Sales of common stock	$ 7			8,270		8,277
Sales of common stock (in Shares)	66,667
Fair value of warrants allocated to proceeds of common stock				1,723		1,723
Shares issued in acquisition of AEU	$ 79			103,725		103,804
Shares issued in acquisition of AEU (in Shares)	871,633
Consultant and director fees payable with common shares and warrants	$ 16		58,252	47,164		105,432
Consultant and director fees payable with common shares and warrants (in Shares)	79,011
Shares and options issued to employees	$ 3		(31,250)	62,364		31,117
Shares and options issued to employees (in Shares)	30,000
Net loss					(1,589,821)	(1,589,821)
Balance at Jun. 30, 2022	$ 23,908	$ 2,750	345,042	39,396,034	(34,963,133)	4,804,601
Balance (in Shares) at Jun. 30, 2022	239,080,428	2,750,000
Sales of shares pursuant to Standby Equity Purchase Agreement	$ 271			297,134		297,405
Sales of shares pursuant to Standby Equity Purchase Agreement (in Shares)	2,708,100
Stock based financing fees	$ 90			99,910		100,000
Stock based financing fees (in Shares)	895,255
Other sales of common stock	$ 493			405,587		406,080
Other sales of common stock (in Shares)	4,931,818
Fair value of warrants allocated to proceeds of common stock				118,920		118,920
Consultant and director fees payable with common shares and warrants	$ 14		43,803	49,036		92,853
Consultant and director fees payable with common shares and warrants (in Shares)	142,024
Shares and options issued to employees	$ 10		(43,500)	43,526		36
Shares and options issued to employees (in Shares)	100,000
Net loss					(1,783,801)	(1,783,801)
Balance at Sep. 30, 2022	$ 24,786	$ 2,750	$ 345,345	$ 40,410,147	$ (36,746,934)	$ 4,036,094
Balance (in Shares) at Sep. 30, 2022	247,857,625	2,750,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows from Operating Activities
Net loss	$ (4,541,745)	$ (8,697,234)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	622,306	623,438
Stock based compensation, including amortization of deferred equity compensation	326,485	574,998
Amortization of debt discount	21,020
Stock-based financing cost	100,000
Loss on extinguishment of debt		4,957,168
Change in fair value of debt		19,246
Change in fair value of contingent acquisition consideration	(665,573)	234,678
Changes in operating assets and liabilities:
Accounts receivable	22,432	(25,831)
Inventory	(40,345)	(11,706)
Prepaid expenses and deposits	29,072	(40,516)
Right of use lease assets	255,632	78,835
Accounts payable and accrued expenses	370,413	800,732
Lease liability	(254,756)	(82,102)
Contract liabilities	(7,585)	(58,890)
Net cash used in operating activities	(3,762,644)	(1,627,184)
Cash Flows from Investing Activities
Acquisition, net of cash acquired	(313,802)
Payment of contingent acquisition consideration	(207,384)	(322,106)
Acquisition of property and equipment	(23,564)	(12,475)
Net cash used in investing activities	(544,750)	(334,581)
Cash Flows from Financing Activities
Proceeds from sale of common stock	706,787	6,949,281
Proceeds from exercise of options and warrants		350,200
Proceeds from notes payable	522,500
Repayment of notes payable	(55,379)	(51,109)
Net cash provided by financing activities	1,173,908	7,248,372
Net (decrease) increase in cash	(3,133,486)	5,286,607
Cash, beginning of period	3,291,646	162,184
Cash, end of period	158,160	5,448,791
Cash paid during the period for interest	2,514	232
Cash paid during the period for income tax
Schedule of non-cash investing and financing activities:
Fair value of shares issued as purchase price consideration	103,804
Common stock issuable issued during period	112,528	192,547
Net carrying value of equity liabilities (assets) written off	21,359
Proceeds from sale of common stock under Standby Equity Purchase Agreement applied to note payable balance	125,618
Debt discount and original issue discount allocated to proceeds of notes payable	38,500
Recognition of operating lease: right of use asset and lease liability	284,905
Forgiveness of government loans		632,826
Fair value of warrants issued for professional service		36,030
Incremental fair value of warrants modified to extend maturity date of convertible notes payable		126,502
Conversion of convertible note payable to common shares		4,061,549
Fair value of warrants issued in connection with conversion of convertible notes payable		3,074,637
Accrued liabilities relieved upon cashless exercise of warrants		614,221
Contingent acquisition consideration payable in common stock		$ 366,300

Business and Business Presentat

Business and Business Presentation	9 Months Ended
	Sep. 30, 2022
Business and Business Presentation [Abstract]
BUSINESS AND BUSINESS PRESENTATION	NOTE 1 - BUSINESS AND BUSINESS PRESENTATION HealthLynked Corp. (the “Company”) was incorporated in the State of Nevada on August 4, 2014. On September 2, 2014, the Company filed Amended and Restated Articles of Incorporation with the Secretary of State of Nevada setting the total number of authorized shares at 250,000,000 shares, which included up to 230,000,000 shares of common stock and 20,000,000 shares of “blank check” preferred stock. On February 5, 2018, the Company filed an Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of Nevada to increase the number of authorized shares of common stock to 500,000,000 shares. The Company currently operates in four distinct divisions: the Health Services Division, the Digital Healthcare Division, the ACO/MSO (Accountable Care Organization / Managed Service Organization) Division, and the Medical Distribution Division. The Health Services division is comprised of the operations of (i) Naples Women’s Center (“NWC”), a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology) and General Practice, (ii) Naples Center for Functional Medicine (“NCFM”), a Functional Medical Practice engaged in improving the health of its patients through individualized and integrative health care, (iii) Bridging the Gap Physical Therapy (“BTG”), a physical therapy practice in Bonita Springs, FL that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery, and (iv) Aesthetic Enhancements Unlimited (“AEU”), a patient service facility specializing in minimally and non-invasive cosmetic services acquired by the Company in May 2022. The Digital Healthcare division develops and operates an online personal medical information and record archive system, the “HealthLynked Network,” which enables patients and doctors to keep track of medical information via the Internet in a cloud-based system. The ACO/MSO Division is comprised of the operations of Cura Health Management LLC (“CHM”) and its subsidiary ACO Health Partners LLC (“AHP”), which were acquired by the Company on May 18, 2020. CHM and AHP operate an Accountable Care Organization (“ACO”) and Managed Service Organization (“MSO”) that assists physician practices in providing coordinated and more efficient care to patients via the Medicare Shared Savings Program (“MSSP”) as administered by the Centers for Medicare and Medicaid Services (the “CMS”), which rewards providers for efficiency in patient care. The Medical Distribution Division is comprised of the operations of MedOffice Direct LLC (“MOD”), a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States. As described in Note 18, “Subsequent Events,” during October 2022, the Company’s Board of Directors approved the sale of the ACO/MSO Division. The Company expects to complete sale by first quarter 2023 and use the cash proceeds generated from the sale to supplement its operating cash requirements and pursue additional acquisitions. These unaudited condensed consolidated financial statements reflect all adjustments including normal recurring adjustments, which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America (“GAAP”). These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the years ended December 31, 2021 and 2020, respectively, which are included in the Company’s Form 10-K, filed with the United States Securities and Exchange Commission (the “Commission”) on March 31, 2022, as amended by the Company’s Form 10-K/A filed with the Commission on June 3, 2022. The Company assumes that the users of the interim financial information herein have read, or have access to, the audited consolidated financial statements for the preceding period, and that the adequacy of additional disclosure needed for a fair presentation may be determined in that context. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of results for the entire year ending December 31, 2022. On a consolidated basis, the Company’s operations are comprised of the parent company, HealthLynked Corp., and its seven subsidiaries: NWC, NCFM, BTG, CHM, AHP, MOD and AEU. All significant intercompany transactions and balances have been eliminated upon consolidation. In addition, certain amounts in the prior periods’ consolidated financial statements have been reclassified to conform to the current period presentation.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Business and Business Presentation [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the presentation of the accompanying consolidated financial statements follows: Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP. All amounts referred to in the notes to the consolidated financial statements are in United States Dollars ($) unless stated otherwise. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about fair valuation of acquired intangible assets, cash flow and fair value assumptions associated with measurements of contingent acquisition consideration and impairment of intangible assets and goodwill, valuation of inventory, collection of accounts receivable, the valuation and recognition of stock-based compensation expense, valuation allowance for deferred tax assets, borrowing rate consideration for right-of-use (“ROU”) lease assets including related lease liability and useful life of fixed assets. Revenue Recognition Patient service revenue Patient service revenue is earned for GYN services provided to patients at our NWC facility, functional medicine services provided to patients at our NCFM facility, and physical therapy services provided to patients at our BTG facility. Patient service revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients and third-party payors (including health insurers and government programs) and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Company bills patients and third-party payors within days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time, which includes prepaid BTG physical therapy bundles for which performance obligations are satisfied over time as visits are incurred, is recognized based on actual charges incurred in relation to total expected charges. The Company believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Revenue for performance obligations satisfied at a point in time, which includes all patient service revenue other than BTG physical therapy bundles, is recognized when goods or services are provided at the time of the patient visit, and at which time the Company is not required to provide additional goods or services to the patient. The Company determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. Estimates of contractual adjustments and discounts require significant judgment and are based on the Company’s current contractual agreements, its discount policies, and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. There were no material changes during the nine months ended September 30, 2022 or 2021 to the judgments applied in determining the amount and timing of patient service revenue. Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows: ● Medicare: ● Medicaid: ● Other: Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Company estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Patient services provided by NCFM, BTG and AEU are provided on a cash basis and not submitted through third party insurance providers. Contract liabilities related to prepaid BTG patient service revenue were $23,015 and $42,530 as of September 30, 2022 and December 31, 2021, respectively. Medicare Shared Savings Revenue The Company earns Medicare shared savings revenue based on performance of the population of patient lives for which it is accountable as an ACO against benchmarks established by the MSSP. Because the MSSP, which was formed in 2012, is relatively new and has limited historical experience, the Company cannot accurately predict the amount of shared savings that will be determined by CMS. Such amounts are determined annually when the Company is notified by CMS of the amount of shared savings earned. Accordingly, the Company recognizes Medicare shared savings revenue in the period in which the CMS notifies the Company of the exact amount of shared savings to be paid, which historically has occurred during the fiscal quarter ended September 30 for the program year ended December 31 of the previous year. Based on the ACO operating agreements, the Company bears all costs of the ACO operations until revenue is recognized. At that point, the Company shares in up to 100% of the revenue to recover its costs incurred. Consulting and Event Revenue Also pursuant to ASC 606, the Company recognizes service revenue as services are provided, with any unearned but paid amounts recorded as a contract liability at each balance sheet date. Contract liabilities related to consulting revenue were $25,000 and $25,000 as of September 30, 2022 and December 31, 2021, respectively. Event revenue, comprised of admission fees for summit events, is recognized when an event is held. Product Revenue Revenue is derived from the distribution of medical products that are sourced from a third party. The Company recognizes revenue at a point in time when title transfers to customers and the Company has no further obligation to provide services related to such products, which occurs when the product ships. The Company is the principal in its revenue transactions and as a result revenue is recorded on a gross basis. The Company has determined that it controls the ability to direct the use of the product provided prior to transfer to a customer, is primarily responsible for fulfilling the promise to provide the product to its customer, has discretion in establishing prices, and ultimately controls the transfer of the product to the customer. Shipping and handling costs billed to customers are recorded in revenue. Contract liabilities related to product revenue were $17,237 and $5,308 as of September 30, 2022 and December 31, 2021, respectively. There were no contract assets as of September 30, 2022 or December 31, 2021. Sales are made inclusive of sales tax, where such sales tax is applicable. Sales tax is applicable on sales made in the state of Florida, where the Company has physical nexus. The Company has determined that it does not have economic nexus in any other states. The Company does not sell products outside of the United States. The Company maintains a return policy that allows customers to return a product within a specified period of time prior to and subsequent to the expiration date of the product. The Company analyzes the need for a product return allowance at the end of each period based on eligible products. Product return allowance was $5,643 and $14,834 as of September 30, 2022 and December 31, 2021, respectively. Contract Liabilities Contract liabilities represent payments from customers for consulting services, patient services and medical products that precede the Company’s service or product fulfillment performance obligation. The Company’s total contract liabilities balance were $65,252 and $72,838 as of September 30, 2022 and December 31, 2021, respectively. Provider shared savings expense Provider shared savings expense represents the ongoing operating expenses of the ACO and annual payments made to the ACO’s participating providers from shared savings revenue payments received from CMS (the “Annual Provider Payment”). The pool of funds available for the Annual Provider Payment, as well as the amounts paid to each individual participating provider from the pool, is determined by ACO management after an annual determination of Medicare shared savings revenue is made by CMS. Expenses related to ongoing operation of the ACO may be deducted from the Medicare shared savings revenue before determining the Annual Provider Payment. Such expenses are recognized in “Provider shared savings expense” as incurred. Expense related to the Annual Provider Payment is recognized in the period in which the size of the Annual Provider Payment pool is determined, which typically corresponds to the period in which the shared saving payment is received from CMS and shared savings revenue is recognized. This typically occurs in the second half of the year following the completion of the program year. Cash and Cash Equivalents For financial statement purposes, the Company considers all highly liquid investments with original maturities of six months or less to be cash and cash equivalents. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. As of September 30, 2022 and December 31, 2021, the Company had $-0- and $2,957,040 in excess of the FDIC insured limit, respectively. Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates 48% of total billings. Trade accounts receivable are recorded at this net amount. As of September 30, 2022 and December 31, 2021, the Company’s gross patient services accounts receivable were $84,905 and $193,363, respectively, and net patient services accounts receivable were $41,349 and $86,287, respectively, based upon net reporting of accounts receivable. The Company also had consulting services receivable of $22,506 and $-0- as of September 30, 2022 and December 31, 2021, respectively. As of September 30, 2022 and December 31, 2021, the Company’s allowance of doubtful accounts was $-0- and $13,972, respectively. Leases Upon transition under ASU 2016-02, the Company elected the suite of practical expedients as a package applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. For new leases, the Company will determine if an arrangement is or contains a lease at inception. Leases are included as ROU assets within other assets and ROU liabilities within accrued expenses and other liabilities and within other long-term liabilities on the Company’s consolidated balance sheets. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s leases do not provide an implicit rate. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. See Note 8 for more complete details on balances as of the reporting periods presented herein. Inventory Inventory consisting of supplements, is stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method. Outdated inventory is directly charged to cost of goods sold. Goodwill and Intangible Assets Goodwill is recognized as the excess cost of an acquired entity over the net amount assigned to assets acquired and liabilities assumed. Goodwill is not amortized, but rather tested for impairment on an annual basis and more often if circumstances require. Impairment losses are recognized whenever the implied fair value of goodwill is less than its carrying value. The Company recognizes an acquired intangible apart from goodwill whenever the intangible arises from contractual or other legal rights, or whenever it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their estimated useful lives unless the estimated useful life is determined to be indefinite. Amortizable intangible assets are being amortized primarily over useful lives of five years. The straight-line method of amortization is used as it has been determined to approximate the use pattern of the assets. Impairment losses are recognized if the carrying amount of an intangible that is subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value. The Company also maintains intangible assets with indefinite lives, which are not amortized. These intangibles are tested for impairment on an annual basis and more often if circumstances require. Impairment losses are recognized whenever the implied fair value of these assets is less than their carrying value. No impairment charges were recognized in the three and nine months ended September 30, 2022 or 2021. Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. The Company relies on a sole supplier for the fulfillment of substantially all of its product sales made through MOD. Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. Convertible Notes Convertible notes are regarded as compound instruments, consisting of a liability component and an equity component. The component parts of compound instruments are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortized cost basis until extinguished upon conversion or at the instrument’s maturity date. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized as additional paid-in capital and included in equity, net of income tax effects, and is not subsequently remeasured. After initial measurement, they are carried at amortized cost using the effective interest method. Convertible notes for which the maturity date has been extended and that qualify for debt extinguishment treatment are recorded at fair value on the extinguishment date and then revalued at the end of each reporting period, with the change recorded to the statement of operations under “Change in Fair Value of Debt.” Government Notes Payable During 2020, the Company and certain of its subsidiaries received loans under the Paycheck Protection Program (the “PPP”). The PPP loans, administered by the U.S. Small Business Administration (the “SBA”), were issued under the Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES Act. Pursuant to the terms of the PPP, principal amounts may be forgiven if loan proceeds are used for qualifying expenses as described in the CARES Act, including costs such as payroll, benefits, employer payroll taxes, rent and utilities. The Company accounts for forgiveness of government loans pursuant to FASB ASC 470, “Debt,” (“ASC 470”). Pursuant to ASC 470, loan forgiveness is recognized in earnings as a gain on extinguishment of debt when the debt is legally released by the lender. Fair Value of Assets and Liabilities Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs: ● Level 1 – ; ● Level 2 ● Level 3 The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a binomial lattice option pricing model to estimate the fair value of options, warrants, beneficial conversion features and other Level 3 financial assets and liabilities. The Company believes that the binomial lattice model results in the best estimate of fair value because it embodies all of the requisite assumptions (including the underlying price, exercise price, term, volatility, and risk-free interest-rate) necessary to fairly value these instruments and, unlike less sophisticated models like the Black-Scholes model, it also accommodates assumptions regarding investor exercise behavior and other market conditions that market participants would likely consider in negotiating the transfer of such an instruments. Stock-Based Compensation The Company accounts for stock-based compensation to employees and nonemployees under ASC 718 “Compensation – Stock Compensation” using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company uses a binomial lattice pricing model to estimate the fair value of options and warrants granted. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. No income tax has been provided for the three and nine months ended September 30, 2022 and 2021, since the Company has sustained a loss for both periods. Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, management has determined a full valuation allowance for the deferred tax assets, since it is more likely than not that the deferred tax assets will not be realizable. Recurring Fair Value Measurements The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, short-term borrowings, accounts payable, accrued liabilities, and derivative financial instruments approximated their fair value. Deemed Dividend The Company incurs a deemed dividend on Series B Convertible Preferred Voting Stock (the “Series B Preferred”). As the intrinsic price per share of the Series B Preferred was less than the deemed fair value of the Company’s common stock on the date of issuance of the Series B Preferred, the Series B Preferred contains a beneficial conversion feature as described in FASB ASC 470-20, “Debt with Conversion and Other Options.” The difference in the stated conversion price and estimated fair value of the common stock is accounted for as a beneficial conversion feature and affects income or loss available to common stockholders for purposes of earnings per share available to common stockholders. The Company incurs further deemed dividends on certain of its warrants containing a down round provision equal to the difference in fair value of the warrants before and after the triggering of the down round adjustment. Net Loss per Share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the three and nine months ended September 30, 2022 and 2021, the Company reported a net loss and excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of September 30, 2022 and December 31, 2021, potentially dilutive securities were comprised of (i) 62,259,569 and 59,796,992 warrants outstanding, respectively, (ii) 3,999,250 and 3,456,250 stock options outstanding, respectively, (iii) 219,768 and 302,050 unissued shares subject to future vesting requirements granted pursuant to the Company’s Employee Incentive Plan, (iv) up to 1,329,469 common shares issuable that are earned but not paid under consulting and director compensation arrangements, and (v) up to 13,750,000 and 13,750,000 shares of common stock issuable upon conversion of Series B Preferred. Common stock awards The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded on the consolidated statement of comprehensive loss in the same manner and charged to the same account as if such settlements had been made in cash. From time to time, the Company also issues stock awards settleable in a variable number of common shares. Such awards are classified as liabilities until such time as the number of shares underlying the grant is determinable. Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes pricing model as of the measurement date. The Company uses a binomial lattice pricing model to estimate the fair value of compensation options and warrants. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period, or at the date of issuance, if there is not a service period. Certain of the Company’s warrants include a so-called down round provision. The Company accounts for such provisions pursuant to ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has four operating segments: Health Services (multi-specialty medical group including the NWC GYN practice, the NCFM functional medicine practice, the BTG physical therapy practice, and the AEU cosmetic services practice), Digital Healthcare (develops and markets the “HealthLynked Network,” an online personal medical information and record archive system), ACO/MSO (comprised of the ACO/MSO business acquired with CHM in May 2020, which assists physician practices in providing coordinated and more efficient care to patients via the MSSP), and Medical Distribution (comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices). Recently Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments”: The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. The Company is currently evaluating the impact the adoption of this guidance may have on its consolidated financial statements. In August 2020, the FASB issued ASU 2020-06 Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) In October 2021, the FASB issued guidance which requires companies to apply Topic 606, Revenue from Contracts with Customers Recently Adopted Pronouncements In December 2019, the FASB issued ASU 2019-12 Simplifying the Accounting for Income Taxes In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The ASU provides guidance to clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and,

Liquidity and Going Concern Ana

Liquidity and Going Concern Analysis	9 Months Ended
	Sep. 30, 2022
Liquidity and Going Concern Analysis [Abstract]
LIQUIDITY AND GOING CONCERN ANALYSIS	NOTE 3 – LIQUIDITY AND GOING CONCERN ANALYSIS Liquidity and Going Concern During the second quarter of 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This update provided U.S. GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. Under this standard, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company’s ability to continue as a going concern, management considered the conditions and events that could raise substantial doubt about the Company’s ability to continue as a going concern within 12 months after the Company’s financial statements were issued (November 14, 2022). Management considered the Company’s current financial condition and liquidity sources, including current funds available, forecasted future cash flows and the Company’s obligations due before November 14, 2023. The Company is subject to a number of risks, including uncertainty related to product development and generation of revenues and positive cash flow from its Digital Healthcare division and a dependence on outside sources of capital. The attainment of profitable operations is dependent on future events, including obtaining adequate financing to fulfill the Company’s growth and operating activities and generating a level of revenues adequate to support the Company’s cost structure. The Company has experienced net losses and cash outflows from operating activities since inception. As of September 30, 2022, the Company had cash balances of $158,160, a working capital deficit of $1,989,943 and an accumulated deficit of $36,746,934. For the nine months ended September 30, 2022, the Company had a net loss of $4,541,745, net cash used by operating activities of $3,762,644, and $1,173,908 provided by financing activities. The Company expects to continue to incur net losses and have significant cash outflows for at least the next 12 months. Management has evaluated the significance of the conditions described above in relation to the Company’s ability to meet its obligations and concluded that, without additional funding, the Company will not have sufficient funds to meet its obligations within one year from the date the condensed consolidated financial statements were issued. On July 5, 2022, the Company entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“Yorkville”) (See Note 13, “Shareholders’ Equity,” below for additional information on the SEPA). Pursuant to the SEPA, the Company shall have the right to sell to Yorkville up to 30,000,000 of its shares of common stock, par value $0.0001 per share, at the Company’s request any time during the three-year commitment period set forth in the SEPA. The sale of common stock pursuant to the SEPA provides the Company with additional cash flow availability for operational purposes. Because the purchase price per share to be paid by Yorkville for the shares of common stock sold by the Company to Yorkville pursuant to the SEPA, if any, will fluctuate based on the market prices of the Company’s common stock during the applicable pricing period, the Company cannot reliably predict the actual purchase price per share to be paid by Yorkville for those shares, or the actual gross proceeds to be raised by the Company from those sales, if any. During the three and nine months ended September 30, 2022, the Company made 11 advances under the SEPA, receiving $297,405 in proceeds for the issuance of 2,708,100 shares of common stock, of which $125,618 was applied to the balance of the Promissory Note (as defined below). On July 19, 2022, the Company issued to Yorkville a promissory note with an initial principal amount equal to $550,000 (the “Promissory Note”) at a purchase price equal to the principal amount of the Promissory Note less any original issue discounts and fees. The Promissory Note will mature on the six-month anniversary of execution (See Note 12, “Notes Payable,” below for additional information). During the three and nine months ended September 30, 2022, the Company made payments of $149,595 against the Promissory Note, including $125,618 applied from proceeds of sales of common stock under the SEPA. The unpaid principal balance as of September 30, 2022 was $411,405. As described further in Note 18, “Subsequent Events,” during October 2022, the Company’s Board of Directors approved a plan to sell the ACO/MSO Division, comprised of the operations of CHM and its subsidiary AHP, which were acquired by the Company on May 18, 2020. CHM and AHP operate an ACO that assists physician practices in providing coordinated and more efficient care to patients via the MSSP, as administered by the CMS, which rewards providers for efficiency in patient care. The Company expects to use the cash proceeds generated from a sale to supplement its operating cash requirements and pursue additional acquisitions. The Company expects to complete a sale by the first quarter of 2023. Without raising additional capital, either via additional advances made pursuant to the SEPA or from other sources, there is substantial doubt about the Company’s ability to continue as a going concern through November 14, 2023. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of presentation contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

Acquisition

Acquisition	9 Months Ended
	Sep. 30, 2022
Acquisition [Abstract]
ACQUISITION	NOTE 4 – ACQUISITION On May 13, 2022, the Company acquired AEU, a patient service facility specializing in minimally and non-invasive cosmetic services including fat reduction, body sculpting, wrinkle reduction, hair removal, IV hydration, and feminine rejuvenation. The Company accounted for the transaction as an acquisition of a business pursuant to ASC 805, “Business Combinations” (“ASC 805”). Following the acquisition, AEU was incorporated into the Company’s Health Services segment. Under the terms of acquisition, the Company paid AEU equity holders consideration of (i) $139,923 cash (less $11,198 cash on hand at AEU as of the closing date), (ii) payment in cash of direct financial obligation of AEU on, or in close proximity to, the date of the business combination, in the amount of $185,077, and (iii) 792,394 shares of Company common stock at closing with a fair value of $103,804 determined using the average closing price of the Company’s common shares for the five days preceding the acquisition date. The total consideration fair value represents a transaction value of $417,606. The following table summarizes the fair value of consideration paid: Fair value of shares issued at closing $ 103,804 Cash consideration 139,923 Payment of AEU debt obligations in cash 185,077 Less cash received (11,198 ) Total Fair Value of Consideration Paid $ 417,606 The following table summarizes the estimated fair values of the identifiable assets acquired and liabilities assumed at the acquisition date: Inventory $ 13,272 Fixed assets 152,759 Right of use lease asset 80,264 Accounts payable and accruals (33,037 ) Loans payable (35,346 ) Lease liability (80,264 ) Fair Value of Identifiable Assets Acquired and Liabilities Assumed $ 97,648 Goodwill of $319,958 arising from the acquisition consists of value associated with the legacy name. None of the goodwill recognized is expected to be deductible for income tax purposes. The following table represents the pro forma consolidated income statement as if AEU had been included in the consolidated results of the Company for the nine months ended September 30, 2022 and 2021. Nine Months Ended 2022 2021 Revenue $ 4,919,274 $ 5,245,035 Net loss $ (4,455,431 ) $ (8,568,344 ) These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of AEU to reflect the additional depreciation that would have been charged assuming the fair value adjustments to property, plant and equipment had been applied on January 1 of the period presented.

Prepaid Expenses and Other

Prepaid Expenses and Other	9 Months Ended
	Sep. 30, 2022
Prepaid Expenses and Other Current Assets [Abstract]
PREPAID EXPENSES AND OTHER	NOTE 5 – PREPAID EXPENSES AND OTHER Prepaid and other expenses as of September 30, 2022 and December 31, 2021 were as follows: September 30, December 31, 2022 2021 Insurance prepayments $ 20,899 $ 25,020 Other expense prepayments 30,910 50,860 Rent deposits 44,125 49,125 Deferred equity compensation 83,125 151,250 Total prepaid expenses and other 179,059 276,255 Less: long term portion (84,091 ) (138,625 ) Prepaid expenses and other, current portion $ 94,968 $ 137,630 Deferred equity compensation reflects common stock grants made in 2021 from the Company’s 2021 Equity Incentive Plan that vest over a four-year period and that are settleable for a fixed dollar amount rather than a fixed number of shares. The original grant date fair value of the equity compensation was $255,000. Amortization was $1,359 and $-0-, respectively, in the three months ended September 30, 2022 and $19,484 and $-0-, respectively, in the nine months ended September 30, 2022 and 2021. At inception, the Company recorded a corresponding liability captioned “Liability-classified equity instruments.”

Property, Plant, and Equipment

Property, Plant, and Equipment	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT, AND EQUIPMENT	NOTE 6 – PROPERTY, PLANT, AND EQUIPMENT Property, plant and equipment as of September 30, 2022 and December 31, 2021 were as follows: September 30, December 31, 2022 2021 Medical equipment $ 493,854 $ 484,126 Furniture, office equipment and leasehold improvements 316,463 149,868 Total property, plant and equipment 810,317 633,994 Less: accumulated depreciation (368,985 ) (283,512 ) Property, plant and equipment, net $ 441,332 $ 350,482 Depreciation expense during the three months ended September 30, 2022 and 2021 was $30,537 and $26,343, respectively. Depreciation expense during the nine months ended September 30, 2022 and 2021 was $85,473 and $80,764, respectively.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL	NOTE 7 – INTANGIBLE ASSETS AND GOODWILL Identifiable intangible assets as of September 30, 2022 and December 31, 2021 were as follows: September 30, December 31, 2022 2021 NCFM: Medical database $ 1,101,538 $ 1,101,538 NCFM: Website 41,000 41,000 CHM: ACO physician contracts 1,073,000 1,073,000 MOD: Website 3,538,000 3,538,000 Total intangible assets 5,753,538 5,753,538 Less: accumulated amortization (1,410,250 ) (873,417 ) Intangible assets, net $ 4,343,288 $ 4,880,121 Goodwill as of September 30, 2022 and December 31, 2021 was as follows: September 30, December 31, 2022 2021 CHM $ 381,856 $ 381,856 MOD 766,249 766,249 AEU 319,958 --- Goodwill $ 1,468,063 $ 1,148,105 Goodwill and intangible assets arose from the acquisitions of NCFM in April 2019, CHM in May 2020, MOD in October 2020, and AEU in May 2022. The NCFM medical database is assumed to have an indefinite life and is not amortized and the website is being amortized on a straight-line basis over its estimated useful life of five years. The CHM ACO physician contracts are assumed to have an indefinite life and are not amortized. The MOD website is being amortized on a straight-line basis over its estimated useful life of five years. Goodwill represents the excess of consideration transferred over the fair value of the net identifiable assets acquired related to the acquisitions of CHM, MOD, and AEU. Amortization expense related to intangible assets in the three months ended September 30, 2022 and 2021 was $178,967 and $178,968, respectively. Amortization expense in the nine months ended September 30, 2022 and 2021 was $536,833 and $542,674, respectively. No impairment charges were recognized related to goodwill and intangible assets in the three and nine months ended September 30, 2022 or 2021.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
LEASES	NOTE 8 – LEASES The Company has separate operating leases for office space related to its NWC, NCFM, BTG and AEU practices, two separate leases relating to its corporate headquarters, and a copier lease that expire in July 2023, May 2025, March 2023, March 2026, November 2023, November 2023 and January 2027, respectively. As of September 30, 2022, the Company’s weighted-average remaining lease term relating to its operating leases was 2.1 years, with a weighted-average discount rate of 11.36%. The table below summarizes the Company’s lease-related assets and liabilities as of September 30, 2022 and December 31, 2021: September 30, December 31, 2022 2021 Lease assets $ 636,267 $ 526,730 Lease liabilities Lease liabilities (short term) $ 378,759 $ 288,966 Lease liabilities (long term) 259,845 239,225 Total lease liabilities $ 638,604 $ 528,191 Lease expense was $123,069 and $99,544 in the three months ended September 30, 2022 and 2021, respectively, and $31,814 and $241,909 in the nine months ended September 30, 2022 and 2021, respectively. Maturities of operating lease liabilities were as follows as of September 30, 2022: 2022 (October to December) $ 119,116 2023 396,833 2024 126,116 2025 74,729 2026 18,148 2027 990 Total lease payments 735,932 Less interest (97,328 ) Present value of lease liabilities $ 638,604

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 9 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Amounts related to accounts payable and accrued expenses as of September 30, 2022 and December 31, 2021 were as follows: September 30, December 31, 2022 2021 Trade accounts payable $ 649,185 $ 306,220 Accrued payroll liabilities 94,106 172,500 Accrued operating expenses 391,653 265,411 Accrued interest 59,349 46,712 $ 1,194,293 $ 790,843

Contract Liabilities

Contract Liabilities	9 Months Ended
	Sep. 30, 2022
Contract Liabilities [Abstract]
CONTRACT LIABILITIES	NOTE 10 – CONTRACT LIABILITIES Amounts related to contract liabilities as of September 30, 2022 and December 31, 2021 were as follows: September 30, December 31, 2022 2021 Patient services paid but not provided $ 23,015 $ 42,530 Consulting services paid but not provided 25,000 25,000 Unshipped products 17,237 5,308 $ 65,252 $ 72,838 Contract liabilities relate to contracted consulting services at CHM for which payment has been made but services have not yet been rendered as of the measurement date, physical therapy services purchased as a prepaid bundle for which services have not yet been provided, and MOD products that have been ordered and paid for by the customer, but which have not been shipped as of the measurement date. The Company typically satisfies its performance obligations related to such contracts, for which payment is typically made prior to the goods or services being provided, upon completion of service or shipment of product.

Amounts Due to Related Party an

Amounts Due to Related Party and Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Amounts Due to Related Party and Related Party Transactions [Abstract]
AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS	NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS Amounts due to related parties as of September 30, 2022 and December 31, 2021 were comprised of deferred compensation payable to the Company’s founder and CEO, Dr. Michael Dent, in the amount of $300,600. The Company paid consulting fees to Dr. Dent’s spouse pursuant to a consulting agreement amounting to $39,038 and $33,462 in the three months ended September 30, 2022 and 2021, respectively, and $100,385 and $111,731 in the nine months ended September 30, 2022 and 2021, respectively.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2022
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 12 – NOTES PAYABLE Notes payable as of September 30, 2022 and December 31, 2021 were as follows: September 30, December 31, 2022 2021 SBA Disaster relief loans $ 450,000 $ 450,000 Promissory note payable to SEPA investor 411,405 --- AEU note payable 7,343 --- Face value of notes payable 868,748 450,000 Less: unamortized discount (20,879 ) --- Notes payable, total 847,869 450,000 Less: long term portion (450,000 ) (450,000 ) Notes payable, current portion $ 397,869 $ --- Government Notes Payable During May and June 2020, the Company and certain of its subsidiaries received an aggregate of $621,069 in loans under the PPP. The Company also acquired a PPP loan in the MOD acquisition with an inception date of April 3, 2020 and a face value of $11,757. The PPP loans, administered by SBA, were issued under the Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES Act. The loans bore interest at 1% per annum and were scheduled to mature in May and June 2022. Principal and interest payments were deferred for the first nine months of the loans. Pursuant to the terms of the PPP, principal amounts may be forgiven if loan proceeds are used for qualifying expenses as described in the CARES Act, including costs such as payroll, benefits, employer payroll taxes, rent and utilities. The entirety of the PPP loans outstanding, comprised of $632,826 principal and $6,503 accrued interest, was forgiven in May 2021. As a result of the forgiveness, the Company recognized a gain on extinguishment of debt in the amount of $632,826 and interest income of $6,503 during the nine months ended September 30, 2021. During June, July and August 2020, the Company and its subsidiaries received an aggregate of $450,000 in Disaster Relief Loans from the SBA. The loans bear interest at 3.75% per annum and mature 30 years from issuance. Mandatory principal and interest payments were originally scheduled to begin 12 months from the inception date of each loan and were subsequently extended by the SBA until 30 months from the inception date. Installment payments are now scheduled to begin in December 2022. Interest accrued on SBA loans as of September 30, 2022 and December 31, 2021 was $37,359 and $24,723, respectively. Interest expense on the loans was $4,252 and $4,226 for the three months ended September 30, 2022 and 2021, respectively, and $12,636 and $12,594 for the nine months ended September 30, 2022 and 2021, respectively. Promissory and Other Notes Payable On July 19, 2022, pursuant to a Note Purchase Agreement between the Company and Yorkville, dated July 5, 2022, the Company issued to Yorkville the Promissory Note with an initial stated principal amount equal to $550,000 at a purchase price equal to the principal amount of the Promissory Note less any original issue discounts and fees. The Promissory Note includes a 5% original issue discount, accrues interest at a rate of 0%, and will be repaid in five equal monthly installments beginning on August 19, 2022. Each monthly installment includes a 2% payment premium, totaling $561,000 in total cash repayments. The Company received net proceeds of $522,500. At inception, the Company recorded a discount against the note of $38,500, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. Amortization expense related to the discount was $18,480 in each of the three and nine months ended September 30, 2022. During the three and nine months ended September 30, 2022, the Company made payments of $149,595 against the Promissory Note , including $125,618 applied from proceeds of sales of common stock under the SEPA. The unpaid principal balance was $411,405 and the unamortized discount balance was $20,020 as of September 30, 2022. In connection with the May 13, 2022 acquisition of AEU, the Company acquired (i) a bank note payable with a remaining principal balance of $9,689 that was repaid in full during July 2022, and (ii) a note payable to a third-party lender (the “AEU Note”) with a remaining principal balance of $29,057, an original issue discount of $3,400, and a net carrying value of $25,657. Amortization expense related to the AEU Note discount was $2,540 in each of the three and nine months ended September 30, 2022. During the three and nine months ended September 30, 2022, the Company made payments of $14,340 and $21,713, respectively, against the Promissory Note. The unpaid principal balance was $7,343 and the unamortized discount balance was $859 as of September 30, 2022. Convertible Notes Payable The Company had no convertible notes payable as of September 30, 2022 or December 31, 2021. On January 6, 2021, the holder of four fixed rate convertible promissory notes with a face value of $1,038,500 – comprised of a $550,000 6% fixed convertible secured promissory note dated July 7, 2016 (the “$550k Note”), a $50,000 10% fixed convertible commitment fee promissory note dated July 7, 2016 (the “$50k Note”), $81,000 of principal remaining on a $111,000 10% fixed convertible secured promissory note dated May 22, 2017 (the “$111k Note”), and a $357,500 10% fixed convertible note dated April 15, 2019 (the “$357.5k Note” and together with the $550k Note, the $50k Note and the $111k Note, the “Extended Notes”) – agreed to extend the maturity date on the Extended Notes to January 14, 2021. In exchange for the extension, the Company agreed to extend the expiration date of 3,508,333 existing warrants held by the holder (the “Extended Warrants”) from dates between July 2021 and March 2022 until March 2023. Because the fair value of consideration issued was greater than 10% of the present value of the remaining cash flows under the modified Extended Notes, the transaction was treated as a debt extinguishment and reissuance of new debt instruments pursuant to the guidance of ASC 470-50. A loss on debt extinguishment was recorded in the amount of $126,502 in the nine months ended September 30, 2021, equal to the incremental fair value of the Extended Warrants before and after the modification. On January 14, 2021, the Company and the holder of the Extended Notes entered into a series of agreements pursuant to which (i) the holder agreed to convert the full face value of $1,038,500 and $317,096 of accrued interest on the Extended Notes into 13,538,494 shares of common stock pursuant to the original conversion terms of the underlying notes, (ii) the holder agreed to a 180-day leak out provision, whereby, from and after January 14, 2021, it may not sell shares of the Company’s common stock in excess of 5% of the Company’s daily trading volume for the first 90 days and 10% of the Company’s daily volume for the next 90 days, subject to certain exceptions, (iii) the holder agreed to release all security interests and share reserves related to the Extended Notes, and (iv) the Company issued to the holder a new five-year warrant to purchase 13,538,494 shares of common stock at an exercise price of $0.30 per share. In connection with the conversion, the Company recognized a loss on debt extinguishment of $5,463,492 in the nine months ended September 30, 2021, representing the excess of the fair value of the shares and warrant issued at conversion over the carrying value of the host instrument and accrued interest. Following the conversion, the Company had no further convertible notes outstanding. Prior to conversion, the Extended Notes were carried at fair value and revalued at each period end, with changes to fair value recorded to the statement of operations under “Change in Fair Value of Debt.” The changes in fair value were $-0- in each of the three months ended September 30, 2022 and 2021 and were $-0- and $19,246 during the nine months ended September 30, 2022 and 2021, respectively. Interest expense on convertible notes outstanding were $-0- and $4,372 during the three and nine months ended September 30, 2021, respectively. There was no interest on convertible notes during the three and nine months ended September 30, 2022.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
SHAREHOLDERS’ EQUITY	NOTE 13 – SHAREHOLDERS’ EQUITY SEPA Advances On July 5, 2022, the Company entered into the SEPA with Yorkville, pursuant to which the Company shall have the right, but not the obligation, to sell to Yorkville up to 30,000,000 of its shares of common stock, par value $0.0001 per share, at the Company’s request any time during the commitment period commencing on July 5, 2022 and terminating on the earliest of (i) the first day of the month following the 36-month anniversary of the SEPA and (ii) the date on which Yorkville shall have made payment of any advances requested pursuant to the SEPA for shares of the Company’s common stock equal to the commitment amount of 30,000,000 shares of common stock. Each SEPA Advance may be for a number of shares of common stock with an aggregate value of up to greater of: (i) an amount equal to thirty percent (30%) of the aggregate daily volume traded of the Company’s common stock for the three (3) trading days immediately preceding notice from the Company of an Advance, or (ii) 2,000,000 shares of common stock. The shares would be purchased at 96.0% of the average of the daily volume weighted average price of the Company’s common stock as reported by Bloomberg L.P. during regular trading hours during each of the three consecutive trading days commencing on the trading day following the Company’s submission of an Advance notice to Yorkville and would be subject to certain limitations, including that Yorkville could not purchase any shares that would result in it owning more than 4.99% of the Company’s outstanding common stock at the time of an Advance. On July 11, 2022, the Company filed a Form S-1 registration statement registering up to 30,000,000 shares of common stock underlying the SEPA. The registration statement was declared effective on July 19, 2022. As consideration for Yorkville’s irrevocable commitment to purchase shares of common stock at the Company’s direction upon the terms and subject to the conditions set forth in the SEPA, upon execution of the SEPA, the Company paid Yorkville’s structuring and due diligence fees of $10,000 in cash and issued to Yorkville 895,255 shares of common stock with a fair value of $100,000 as a commitment fee. During the three and nine months ended September 30, 2022, the Company recognized $110,000 in other expense “Financing Cost” in the accompanying consolidated statement of operations. During the three and nine months ended September 30, 2022, the Company made 11 advances under the SEPA, receiving $297,405 in proceeds for the issuance of 2,708,100 shares of common stock, of which $125,618 was applied to the balance of the Promissory Note. Private Placements During the nine months ended September 30, 2022, the Company sold 4,998,485 shares of common stock to six separate investors in private placement transactions. The Company received $535,000 in proceeds from the sales. In connection with the stock sales, the Company also issued 3,249,244 five During the nine months ended September 30, 2021, the Company sold 13,161,943 shares of common stock in 53 separate private placement transactions. The Company received $4,328,725 in proceeds from the sales. In connection with these stock sales, the Company also issued 6,581,527 five Prior Investment Agreement Draws During the nine months ended September 30, 2021, the Company issued 3,006,098 common shares pursuant to draws made by the Company under the now-expired July 2016 $3 million investment agreement and received an aggregate of $900,636 in net proceeds from the draws. Shares issued to Consultants During the nine months ended September 30, 2022 and 2021, the Company issued 305,524 and 677,242 common shares, respectively, to consultants for services rendered. In connection with the issuances, the Company recognized expenses totaling $37,696 and $151,322 in the nine months ended September 30, 2022 and 2021, respectively. Common Stock Issuable As of September 30, 2022 and December 31, 2021, the Company was obligated to issue the following shares: September 30, 2022 December 31, 2021 Amount Shares Amount Shares Shares issuable to consultants, employees and directors $ 345,345 1,329,469 $ 282,347 719,366 Stock Warrants Transactions involving our stock warrants during the nine months ended September 30, 2022 and 2021 are summarized as follows: 2022 2021 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 59,796,992 $ 0.25 51,352,986 $ 0.17 Granted during the period 3,249,244 $ 0.17 22,421,026 $ 0.39 Exercised during the period --- $ --- (13,637,020 ) $ (0.18 ) Expired during the period (786,667 ) $ (0.44 ) --- $ --- Outstanding at end of the period 62,259,569 $ 0.24 60,136,992 $ 0.25 Exercisable at end of the period 62,259,569 $ 0.24 60,136,992 $ 0.25 Weighted average remaining life 2.6 years 3.4 years The following table summarizes information about the Company’s stock warrants outstanding as of September 30, 2022: Warrants Outstanding Warrants Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.0001 to 0.09 14,789,573 2.3 $ 0.07 14,789,573 $ 0.07 $ 0.10 to 0.24 12,690,290 2.7 $ 0.17 12,690,290 $ 0.17 $ 0.25 to 0.49 31,319,782 2.6 $ 0.31 31,319,782 $ 0.31 $ 0.50 to 1.05 3,459,924 3.8 $ 0.69 3,459,924 $ 0.69 $ 0.05 to 1.00 62,259,569 2.6 $ 0.24 62,259,569 $ 0.24 During the nine months ended September 30, 2022 and 2021, the Company issued 3,249,244 and 22,421,026 warrants, respectively, the aggregate grant date fair value of which was $151,909 and $5,823,476, respectively. The fair value of the warrants was calculated using the following range of assumptions: 2022 2021 Pricing model utilized Binomial Lattice Binomial Lattice Risk free rate range 2.94% 0.38% to 0.97% Expected life range (in years) 5.00 years 3.00 to 5.00 years Volatility range 74.50% 170.58% to 193.21% Dividend yield 0.00% 0.00% There were no warrants exercised during the nine months ended September 30, 2022. During the nine months ended September 30, 2021, the Company received $333,750 upon the exercise of 3,065,278 warrants with exercise prices between $0.09 and $0.15. Additionally, the Company issued 9,047,332 shares upon cashless exercise of 10,571,742 warrant shares exercised using a cashless exercise feature in settlement of litigation and other disputes amounts totaling $614,221 that had been accrued in 2020. Employee Equity Incentive Plans On January 1, 2016, the Company adopted the 2016 Employee Equity Incentive Plan (the “2016 EIP”) for the purpose of having equity awards available to allow for equity participation by its employees. The 2016 EIP allowed for the issuance of up to 15,503,680 shares of the Company’s common stock to employees, which may be issued in the form of stock options, stock appreciation rights, or common shares. The 2016 EIP is governed by the Company’s board, or a committee that may be appointed by the board in the future. The 2016 EIP expired during 2021 but allows for the prospective issuance of shares of common stock subject to vesting of awards made prior to expiration of the 2016 EIP. On September 9, 2021, the Company adopted the 2021 Employee Equity Incentive Plan (the “2021 EIP” and, together with the 2016 EIP, the “EIPs”) for the purpose of having equity awards available to allow for equity participation by its employees. The 2021 EIP allows for the issuance of up to 20,000,000 shares of the Company’s common stock to employees, which may be issued in the form of stock options, stock appreciation rights, or common shares. The 2021 EIP is governed by the Company’s board, or a committee that may be appointed by the board in the future. Amounts recognized in the financial statements with respect to the EIPs in the nine months ended September 30, 2022 and 2021 were as follows: 2022 2021 Total cost of share-based payment plans during the period $ 335,860 $ 574,998 Amounts capitalized in deferred equity compensation during period $ --- $ --- Amounts charged against income for amounts previously capitalized $ (9,375 ) $ --- Amounts charged against income, before income tax benefit $ 326,485 $ 574,998 Amount of related income tax benefit recognized in income $ --- $ --- Stock Options Stock options granted under the EIPs typically vest over a period of three to four years or based on achievement of Company and individual performance goals. The following table summarizes stock option activity as of and for the nine months ended September 30, 2022 and 2021: 2022 2021 Weighted Weighted Average Average Exercise Exercise Stock options Number Price Number Price Outstanding at beginning of period 3,456,250 $ 0.23 3,111,750 $ 0.20 Granted during the period 975,000 $ 0.16 80,000 $ 0.75 Exercised during the period (12,500 ) $ (0.26 ) (145,500 ) $ (0.11 ) Forfeited during the period (419,500 ) $ (0.31 ) (32,500 ) $ (0.16 ) Outstanding at end of period 3,999,250 $ 0.20 3,013,750 $ 0.22 Options exercisable at period-end 2,655,500 $ 0.20 2,173,750 $ 0.19 As of September 30, 2022, there was $150,101 of total unrecognized compensation cost related to options granted under the EIPs. That cost is expected to be recognized over a weighted-average period of 2.2 years. The total fair value of options vested during the nine months ended September 30, 2022 and 2021 was $42,966 and $64,321, respectively. The aggregate intrinsic value of share options exercised during the nine months ended September 30, 2022 and 2021 was $388 and $98,335, respectively. The weighted-average grant-date fair value of option grants made during the nine months ended September 30, 2022 and 2021 was $0.09 per share and $0.62 per share, respectively. During the nine months ended September 30, 2022, the Company issued 1,394 shares upon cashless exercise of 12,500 option shares exercised using a cashless exercise feature. During the nine months ended September 30, 2021, the Company received $16,450 upon the exercise of 145,500 options with exercise prices between $0.10 and $0.252. The fair value of each stock option award is estimated on the date of grant using a binomial lattice option-pricing model based on the assumptions noted in the following table. The Company’s accounting policy is to estimate forfeitures in determining the amount of total compensation cost to record each period. The fair value of options granted for the nine months ended September 30, 2022 and 2021 was calculated using the following range of assumptions: 2022 2021 Pricing model utilized Binomial Lattice Binomial Lattice Risk free rate range 2.81% to 2.90% 1.47% to 2.90% Expected life range (in years) 10.00 years 10.00 years Volatility range 74.38% to 74.50% 74.38% to 192.25% Dividend yield 0.00% 0.00% The following table summarizes the status and activity of nonvested options issued pursuant to the EIPs as of and for the nine months ended September 30, 2022 and 2021: 2022 2021 Weighted Weighted Average Average Grant Date Grant Date Stock options Shares Fair Value Shares Fair Value Nonvested options at beginning of period 858,750 $ 0.23 1,044,375 $ 0.21 Granted 975,000 $ 0.09 80,000 $ 0.62 Vested (195,750 ) $ (0.22 ) (255,000 ) $ (0.25 ) Forfeited (294,250 ) $ (0.26 ) (29,375 ) $ (0.12 ) Nonvested options at end of period 1,343,750 $ 0.12 840,000 $ 0.24 Stock Grants Stock grant awards made under the EIPs typically vest either immediately or over a period of up to four years. The following table summarizes stock grant activity as of and for the nine months ended September 30, 2022 and 2021: 2022 2021 Weighted Weighted Average Average Grant Date Grant Date Stock Grants Shares Fair Value Shares Fair Value Nonvested grants at beginning of period 302,050 $ 0.27 200,000 $ 0.17 Granted 377,454 $ 0.17 1,015,047 $ 0.27 Vested (354,782 ) $ (0.23 ) (1,075,047 ) $ (0.26 ) Forfeited (104,954 ) $ (0.19 ) (50,000 ) $ (0.10 ) Nonvested grants at end of period 219,768 $ 0.20 90,000 $ 0.19 As of September 30, 2022, there was $22,538 of total unrecognized compensation cost related to stock grants made under the EIPs. That cost is expected to be recognized over a weighted-average period of 1.1 years. The weighted-average grant-date fair value of share grants made during the nine months ended September 30, 2022 and 2021 was $0.12 per share and $0.27 per share, respectively. The aggregate fair value of share grants that vested during the nine months ended September 30, 2022 and 2021 was $44.820 and $270,918, respectively. The fair value of each stock grant is calculated using the closing sale price of the Company’s common stock on the date of grant using. The Company’s accounting policy is to estimate forfeitures in determining the amount of total compensation cost to record each period. Liability-Classified Equity Instruments During 2021, the Company made certain compensation stock grants from the 2021 EIP that vest over a four-year period and that are settleable for a fixed dollar amount rather than a fixed number of shares. The original grant date fair value of the equity compensation was $165,000. The Company recognized an asset captioned “Deferred equity compensation” and an offsetting liability captioned as a “Liability-classified equity instrument.” During the nine months ended September 30, 2022, the Company (i) replaced certain variable share contracts with a new fixed share compensation structure and accordingly de-recognized $25,000 of deferred stock compensation and liability-classified equity instruments, and (ii) de-recognized $106,141 of deferred stock compensation and $135,000 of liability-classified equity instruments as a result of the termination of the employee and related future equity rights to which the equity asset and liability related. During 2022, the Company made an additional grant of stock options from the 2021 EIP with a fixed fair value that may be earned based on achievement of performance targets on a quarterly basis through June 2025. The fixed value of $90,000 was recognized as deferred stock compensation and liability-classified equity instruments. The Company also de-recognized $7,500 of deferred stock compensation and liability-classified equity instruments related to this grant based on the target not being achieved for the third quarter of 2022. Amortization of deferred stock compensation assets in the three and nine months ended September 30, 2022 was $1,359 and $14,484, respectively. There was no amortization related to deferred stock compensation assets in the three or nine months ended September 30, 2021. The liability will be converted to equity if and when shares are earned and issued pursuant to prescribed vesting events.

Contingent Acquisition Consider

Contingent Acquisition Consideration	9 Months Ended
	Sep. 30, 2022
Contingent Acquisition Consideration [Abstract]
CONTINGENT ACQUISITION CONSIDERATION	NOTE 14 – CONTINGENT ACQUISITION CONSIDERATION Contingent acquisition consideration relates to future earn-out payments potentially payable related to the Company’s acquisitions of Hughes Center for Functional Medicine (“HCFM”) in 2019 and CHM and MOD in 2020. The terms of the earn-outs related to each acquisition require the Company to pay the former owners additional acquisition consideration for the achievement of prescribed revenue and/or earnings targets for performance of the underlying business for up to four years after the respective acquisition date. Contingent acquisition consideration for each entity is recorded at fair value using a probability-weighted discounted cash flow projection. The fair value of the contingent acquisition consideration is remeasured at the end of each reporting period and changes are included in the statement of operations under the caption “Change in fair value of contingent acquisition consideration.” Contingent acquisition consideration as of September 30, 2022 and December 31, 2021 was comprised of the following: September 30, December 31, 2022 2021 Fair value of HCFM contingent acquisition consideration $ --- $ 172,124 Fair value of CHM contingent acquisition consideration 218,236 276,529 Fair value of MOD contingent acquisition consideration 94,497 737,037 Total contingent acquisition consideration 312,733 1,185,690 Less: long term portion (184,659 ) (782,224 ) Contingent acquisition consideration, current portion $ 128,074 $ 403,466 During the three and nine months ended September 30, 2022 and 2021, the Company recognized gains (losses) on the change in the fair value of contingent acquisition consideration as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 HCFM contingent acquisition consideration $ --- $ (14,316 ) $ (35,259 ) $ (63,769 ) CHM contingent acquisition consideration 62,516 (116,150 ) 58,292 (54,848 ) MOD contingent acquisition consideration 70,967 256,877 642,540 (116,061 ) $ 133,483 $ 126,411 $ 665,573 $ (234,678 ) Maturities of contingent acquisition consideration were as follows as of September 30, 2022: 2022 (October to December) $ 92,546 2023 85,169 2024 135,018 $ 312,733 Hughes Center for Functional Medicine Acquisition – April 2019 On April 12, 2019, the Company acquired a 100% interest in HCFM, a medical practice engaged in improving the health of its patients through individualized and integrative health care. Following the acquisition, HCFM was rebranded as NCFM and was combined with NWC to form the Company’s Health Services segment. Under the terms of acquisition, the Company paid the seller $500,000 in cash, issued 3,968,254 shares of the Company’s common stock and agreed to an earn-out provision of $500,000 that may be earned based on the performance of NCFM in the years ended on the first, second and third anniversary dates of the acquisition closing. The total consideration fair value represented a transaction fair value of $1,764,672. In May 2020, the Company paid the seller $47,000 in satisfaction of the year 1 earn out. In May 2021, the Company paid the seller $196,000 in satisfaction of the year 2 earn out. In May 2022, the Company paid the seller $207,384 in satisfaction of the year 3 earn out. The Company has no further earn out obligations related to the NCFM acquisition. Cura Health Management LLC Acquisition – May 2020 On May 18, 2020, the Company acquired a 100% interest in CHM and its wholly owned subsidiary AHP. CHM and AHP assist physician practices in providing coordinated and more efficient care to patients via the MSSP. The Company accounted for the transaction as an acquisition of a business pursuant to ASC 805. Following the acquisition and through third quarter 2022, the business of CHM comprised the Company’s ACO/MSO Division. Under the terms of acquisition, the Company paid CHM shareholders the following consideration: (i) $214,000 in cash paid at closing, (ii) 2,240,838 shares of the Company’s common stock issued at closing, (iii) up to $223,500 additional cash and $660,000 in additional shares of the Company’s common stock payable at the time CHM receives the final assessment of the calculation of MSSP savings for the 2019 program year, with this amount prorated based on a target MSSP payment (plus other ancillary revenue) of $1,725,000, and (iv) up to $437,500 based on the business achieving annual revenue of $2,250,000 and annual profit of $500,000 in each of the four years following closing. The terms of the earn out required the Company to pay the former owners of CHM (i) up to $223,500 additional cash and to $660,000 of additional shares of Company common stock when CHM receives the final assessment of the calculation of 2019 plan year MSSP revenue (the “Current Earnout”), and (ii) up to $62,500, $125,000, $125,000 and $125,000 on the first, second, third and fourth anniversary, respectively, based on achievement by the underlying business of revenue of at least $2,250,000 (50% weighting) and profit of at least $500,000 (50% weighting) in the year preceding each anniversary date (the “Future Earnout”). During September 2020, pursuant to a Second Amendment to the Agreement and Plan of Merger (the “Second Amendment”) and in satisfaction of the Current Earnout, the Company paid $90,389 cash, issued 1,835,625 shares of the Company’s common stock and agreed that the balance of the Current Earnout that was not earned in 2020, being $124,043 cash and $366,300 in shares of Company common stock, would be deferred until the first future earnout year in which MSSP revenue exceeds $1.725 million and revenue from other services exceeds $605,000 (the “Residual Earnout”). During September 2021, the Company was notified of the amount of Medicare shared savings and received payment for plan year 2020 in the amount of $2,419,312. Because the shared saving payment exceeded $1.725 million, the sellers were paid $124,043 cash and issued 806,828 shares of Company common stock with a value of $366,300 pursuant to the Residual Earnout. Following the payments, the Company had no further obligations under the Residual Earnout. The Company also determined that the sellers did not earn any of the $62,500 year-one Future Earnout related to the performance period May 19, 2020 to May 18, 2021. MedOffice Direct LLC Acquisition – October 2020 On October 19, 2020, the Company acquired a 100% interest in MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States. With over 13,000 name brand medical products in over 150 different categories, MOD leverages pricing discounts with a small unit-of-measure direct-to-consumer shipping model to make ordering medical supplies more convenient and cost effective for its users. The Company accounted for the transaction as an acquisition of a business pursuant to ASC 805. Following the acquisition, the business of MOD comprised the Company’s Medical Distribution Division. Under the terms of acquisition, the Company paid the following consideration: (i) 19,045,563 shares of Company common stock issued at closing, (ii) partial satisfaction of certain outstanding debt obligations of MOD in the amount of $703,200 in cash paid by the Company, and (iii) up to 10,004,749 restricted shares of the Company’s common stock over a four-year period based on MOD achieving revenue targets in calendar years 2021 through 2024 of $1,500,000, $1,875,000, $2,344,000, and $2,930,000, respectively. The first year of earnout measured based on performance in calendar year 2021 was not met.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 15 – COMMITMENTS AND CONTINGENCIES Contracts Related to Medicare Shared Savings Revenue The Company acquired CHM and its subsidiary AHP on May 18, 2020. CHM and AHP combine to operate an ACO under the terms of the MSSP as administered by the CMS. The MSSP is a program created under the Affordable Care Act (the “ACA,” also known as “Obamacare”) designed to enhance the efficiency of healthcare provided to patients covered by Medicare. The program allows for the creation of ACOs, which are organizations that agree to take responsibility for the efficiency of healthcare services provided by a group of participating healthcare providers under Medicare. The ACO is held accountable for the efficiency of the healthcare services of its participating providers as measured against benchmarks prescribed in the MSSP and earns shared savings payments if such benchmarks are met. The Company, via AHP, is party to a Medicare Shared Savings Program Accountable Care Organization Participation Agreement with the CMS that establishes AHP as an ACO. The agreement is effective through December 31, 2024. The Company must comply with the terms and conditions of the agreement in order to maintain its status as an ACO and generate shared savings revenue. The Company, via CHM, is party to approximately 33 separate participant agreements with participating providers that are members of the Company’s ACO with expiration dates through 2024. These agreements include certain restrictions and requirements to which the participating providers must adhere in order to maintain participation in the ACO. Supplier Concentration The Company relies on a single supplier for the fulfillment of approximately 96% of its product sales made through MOD. Service contracts The Company carries various service contracts on its office buildings & certain copier equipment for repairs, maintenance and inspections. All contracts are short term and can be cancelled. Litigation None. Leases Maturities of operating lease liabilities were as follows as of September 30, 2022: 2022 (October to December) $ 119,116 2023 396,833 2024 126,116 2025 74,729 2026 18,148 2027 990 Total lease payments 735,932 Less interest (97,328 ) Present value of lease liabilities $ 638,604 Employment/Consulting Agreements The Company has employment agreements with certain of its physicians, nurse practitioners and physical therapists in the Health Services division. The agreements generally call for a fixed salary at the beginning of the contract with a transaction to performance-based pay later in the contract. On October 13, 2022, the Company entered into an offer letter (the “Agreement”) with George O’Leary in his continuing capacity as Chief Financial Officer of the Company. The Agreement was effective as of July 1, 2022 and provides that Mr. O’Leary’s base salary will be $259,000 per year, with annual review and adjustment at the discretion of the Chief Executive Officer and Compensation Committee of the Board of Directors of the Company, and an annual incentive bonus of 25% of annual salary based on the achievement of the Company of certain financial metrics as approved by the Compensation Committee. In addition, Mr. O’Leary will be eligible for a cash bonus of $50,000 upon the uplisting of the Company and completion of a financing round at the time of uplisting. The Agreement also provides that Mr. O’Leary will receive a grant of 100,000 shares of restricted stock upon execution of the Agreement and additional grants of 100,000 restricted shares on each of July 1, 2023, 2024 and 2025. Mr. O’Leary was also granted 1,200,000 stock options with an exercise price of $0.06, a portion of which are subject to time vesting and a portion of which are subject to vesting upon the achievement of certain of the Company’s corporate objectives and Mr. O’Leary’s individual objectives. If Mr. O’Leary is terminated without cause the Company will provide Mr. O’Leary as severance an amount equal to six (6) months of his base salary. Concurrently, the Company and Mr. O’Leary entered into a Non-Disclosure, Non-Solicitation and Non-Compete Agreement, effective as of September 20, 2022 that contains a non-solicitation and non-compete provision which will be in effect for a two-year period following the termination of Mr. O’Leary’s employment relationship with the Company; provided, however, such period is shortened to six (6) months if Mr. O’Leary is terminated without cause. On July 1, 2016, the Company entered into an employment agreement with Dr. Michael Dent, Chief Executive Officer and a member of the Board of Directors. Dr. Dent’s employment agreement continues until terminated by Dr. Dent or the Company. If Dr. Dent’s employment is terminated by the Company (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Dr. Dent will be entitled to severance in an amount equal to 12 months of his then-current annual base salary, as well as the pro-rata portion of any bonus that would be due and payable to him. In the event that Dr. Dent terminates the employment agreement, he shall be entitled to any accrued but unpaid salary and other benefits up to and including the date of termination, and the pro-rata portion of any unvested time-based options up until the date of termination. On May 18, 2020, the Company entered into separate 4-year consulting services agreements with each of the two principals of the ACO/MSO business acquired in May 2020 that call for each person to earn fixed annual consulting fees and a share of Medicare shared savings revenue, consulting revenue and overall profits generated by the underlying business. Litigation From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. The Company is not aware of any such legal proceedings that will have, individually or in the aggregate, a material adverse effect on its business, financial condition or operating results.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 16 – SEGMENT REPORTING The Company has four reportable segments: Health Services, Digital Healthcare, ACO/MSO and Medical Distribution. The Health Services division is comprised of the operations of (i) NWC, a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology), and General Practice, (ii) NCFM, a Functional Medical Practice acquired in April 2019 that is engaged in improving the health of its patients through individualized and integrative health care, and (iii) BTG, a physical therapy practice in Bonita Springs, FL that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery. The Digital Healthcare segment develops and plans to operate an online personal medical information and record archive system, the “HealthLynked Network,” which will enable patients and doctors to keep track of medical information via the Internet in a cloud-based system. The ACO/MSO Division is comprised of the business acquired with CHM, which assists physician practices in providing coordinated and more efficient care to patients via the MSSP as administered by the CMS, which rewards providers for efficiency in patient care. The Medical Distribution Division is comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States. The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. Segment information for the three months ended September 30, 2022 was as follows: Three Months Ended September 30, 2022 Health Services Digital Healthcare ACO / MSO Medical Distribution Total Revenue Patient service revenue, net $ 1,262,253 $ --- $ --- $ --- $ 1,262,253 Subscription, consulting and event revenue --- 1,171 88,806 --- 89,977 Product revenue --- --- --- 95,449 95,449 Total revenue 1,262,253 1,171 88,806 95,449 1,447,679 Operating Expenses Practice salaries and benefits 810,058 --- --- --- 810,058 Other practice operating expenses 695,300 --- --- --- 695,300 Medicare shared savings expenses --- --- 337,533 --- 337,533 Cost of product revenue --- --- --- 87,775 87,775 Selling, general and administrative expenses --- 1,055,178 --- 32,955 1,088,133 Depreciation and amortization 31,198 1,406 --- 176,900 209,504 Total Operating Expenses 1,536,556 1,056,584 337,533 297,630 3,228,303 (Loss) income from operations $ (274,303 ) $ (1,055,413 ) $ (248,727 ) $ (202,181 ) $ (1,780,624 ) Other Segment Information Interest expense (income) $ 2,815 $ 2,825 $ --- $ --- $ 5,640 Financing cost $ 110,000 $ --- $ --- $ --- $ 110,000 Amortization of original issue discounts on notes payable $ 18,480 $ 2,540 $ --- $ --- $ 21,020 Change in fair value of contingent acquisition consideration $ --- $ (133,483 ) $ --- $ --- $ (133,483 ) Segment information for the nine months ended September 30, 2022 was as follows: Nine Months Ended September 30, 2022 Health Services Digital Healthcare ACO / MSO Medical Distribution Total Revenue Patient service revenue, net $ 4,069,714 $ --- $ --- $ --- $ 4,069,714 Subscription, consulting and event revenue --- 9,433 251,058 --- 260,491 Product revenue --- --- --- 372,877 372,877 Total revenue 4,069,714 9,433 251,058 372,877 4,703,082 Operating Expenses Practice salaries and benefits 2,344,529 --- --- --- 2,344,529 Other practice operating expenses 1,897,070 --- --- --- 1,897,070 Medicare shared savings expenses --- --- 802,411 --- 802,411 Cost of product revenue --- --- --- 419,129 419,129 Selling, general and administrative expenses --- 3,529,289 --- 149,495 3,678,784 Depreciation and amortization 87,134 4,472 --- 530,700 622,306 Total Operating Expenses 4,328,733 3,533,761 802,411 1,099,324 9,764,229 Income (loss) from operations $ (259,019 ) $ (3,524,328 ) $ (551,353 ) $ (726,447 ) $ (5,061,147 ) Other Segment Information Interest expense (income) $ 8,420 $ 6,731 $ --- $ --- $ 15,151 Financing cost $ 110,000 $ --- $ --- $ --- $ 110,000 Amortization of original issue discounts on notes payable $ 18,480 $ 2,540 $ --- $ --- $ 21,020 Change in fair value of contingent acquisition consideration $ --- $ (665,573 ) $ --- $ --- $ (665,573 ) September 30, 2022 Identifiable assets $ 2,182,272 $ 507,030 $ 1,132,696 $ 2,188,509 $ 6,010,507 Goodwill $ 319,958 $ --- $ 381,856 $ 766,249 $ 1,468,063 December 31, 2021 Identifiable assets $ 2,152,533 $ 3,450,332 $ 1,167,965 $ 2,775,621 $ 9,546,451 Goodwill $ --- $ --- $ 381,856 $ 766,249 $ 1,148,105 Segment information for the three months ended September 30, 2021 was as follows: Three Months Ended September 30, 2021 Health Services Digital Healthcare ACO / MSO Medical Distribution Total Revenue Patient service revenue, net $ 1,394,356 $ --- $ --- $ --- $ 1,394,356 Medicare shared savings revenue --- --- 2,419,312 --- 2,419,312 Subscription, consulting and event revenue --- --- 69,595 --- 69,595 Product revenue --- --- --- 161,456 161,456 Total revenue 1,394,356 --- 2,488,907 161,456 4,044,719 Operating Expenses Practice salaries and benefits 739,024 --- --- --- 739,024 Other practice operating expenses 549,086 --- --- --- 549,086 Medicare shared savings expenses --- --- 1,748,585 --- 1,748,585 Cost of product revenue --- --- --- 145,432 145,432 Selling, general and administrative expenses --- 1,093,461 --- 54,130 1,147,591 Depreciation and amortization 26,196 2,215 --- 176,900 205,311 Total Operating Expenses 1,314,306 1,095,676 1,748,585 376,462 4,535,029 Loss from operations $ 80,050 $ (1,095,676 ) $ 740,322 $ (215,006 ) $ (490,310 ) Other Segment Information Interest expense (income) $ 2,706 $ 1,412 $ --- $ --- $ 4,118 Change in fair value of contingent acquisition consideration $ --- $ (126,411 ) $ --- $ --- (126,411 ) Segment information for the nine months ended September 30, 2021 was as follows: Nine Months Ended September 30, 2021 Health Digital ACO / Medical Total Revenue Patient service revenue, net $ 4,379,282 $ --- $ --- $ --- $ 4,379,282 Medicare shared savings revenue --- --- 2,419,312 --- 2,419,312 Subscription, consulting and event revenue --- 11,905 217,209 --- 229,114 Product revenue --- --- --- 512,325 512,325 Total revenue 4,379,282 11,905 2,636,521 512,325 7,540,033 Operating Expenses Practice salaries and benefits 2,305,993 --- --- --- 2,305,993 Other practice operating expenses 1,790,874 --- --- --- 1,790,874 Medicare shared savings expenses --- --- 2,157,555 --- 2,157,555 Cost of product revenue --- --- --- 474,026 474,026 Selling, general and administrative expenses --- 3,472,493 --- 188,713 3,661,206 Depreciation and amortization 83,493 3,405 --- 536,540 623,438 Total Operating Expenses 4,180,360 3,475,898 2,157,555 1,199,279 11,013,092 Income (loss) from operations $ 198,922 $ (3,463,993 ) $ 478,966 $ (686,954 ) $ (3,473,059 ) Other Segment Information Interest expense (income) $ 5,145 $ 8,038 $ --- $ (100 ) $ 13,083 (Gain) loss on extinguishment of debt $ (502,959 ) $ 5,471,884 $ --- $ (11,757 ) $ 4,957,168 Change in fair value of debt $ --- $ 19,246 $ --- $ --- $ 19,246 Change in fair value of contingent acquisition consideration $ --- $ 234,678 $ --- $ --- $ 234,678 September 30, 2021 Identifiable assets $ 2,104,819 $ 3,967,850 $ 2,850,949 $ 2,890,389 $ 11,814,007 Goodwill $ --- $ --- $ 381,856 $ 766,249 $ 1,148,105 The Digital Healthcare made intercompany sales of $180 and $400 in the three months ended September 30, 2022 and 2021, respectively, and $640 and $743 in the nine months ended September 30, 2022 and 2021, respectively, related to subscription revenue billed to and paid for by the Company’s physicians for access to the HealthLynked Network. The Medical Distribution segment made intercompany sales of $3,144 and $-0- in the three months ended September 30, 2022 and 2021, respectively, and $25,214 and $-0- in the nine months ended September 30, 2022 and 2021, respectively, related to medical products sold to practices in the Company’s Health Services segment. Intercompany revenue and the related costs are eliminated on consolidation.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	NOTE 17 – FAIR VALUE OF FINANCIAL INSTRUMENTS The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate their respective fair values due to the short-term nature of such instruments. The Company measures certain financial instruments at fair value on a recurring basis, including certain convertible notes payable and related party loans, which were extinguished and reissued and are therefore subject to fair value measurement, derivative financial instruments arising from conversion features embedded in convertible promissory notes for which the conversion rate was not fixed, and equity-class. All financial instruments carried at fair value fall within Level 3 of the fair value hierarchy as their value is based on unobservable inputs. The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2022 and December 31, 2021: As of September 30, 2022 As of December 31, 2021 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Liability-classified equity instruments $ --- $ --- $ 83,125 $ 83,125 $ --- $ --- $ 162,500 $ 162,500 Contingent acquisition consideration --- --- 312,733 312,733 --- --- 1,185,690 1,185,690 Total $ --- $ --- $ 395,858 $ 395,858 $ --- $ --- $ 1,348,190 $ 1,348,190 The changes in Level 3 financial instruments that are measured at fair value on a recurring basis during the three and nine months ended September 30, 2022 and 2021 were as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Convertible notes payable $ --- $ --- $ --- $ (19,246 ) Contingent acquisition consideration 133,483 126,411 665,573 (234,678 ) Total $ 133,483 $ 126,411 $ 665,573 $ (253,924 )

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 18 – SUBSEQUENT EVENTS On October 13, 2022, the Company entered into the Agreement with George O’Leary in his continuing capacity as Chief Financial Officer of the Company. The Agreement was effective as of July 1, 2022 and provides that Mr. O’Leary’s base salary will be $259,000 per year, with annual review and adjustment at the discretion of the Chief Executive Officer and Compensation Committee of the Board of Directors of the Company, and an annual incentive bonus of 25% of annual salary based on the achievement of the Company of certain financial metrics as approved by the Compensation Committee. In addition, Mr. O’Leary will be eligible for a cash bonus of $50,000 upon the uplisting of the Company and completion of a financing round at the time of uplisting. The Agreement also provides that Mr. O’Leary will receive a grant of 100,000 shares of restricted stock upon execution of the Agreement and additional grants of 100,000 restricted shares on each of July 1, 2023, 2024 and 2025. Mr. O’Leary was also granted 1,200,000 stock options with an exercise price of $0.06, a portion of which are subject to time vesting and a portion of which are subject to vesting upon the achievement of certain of the Company’s corporate objectives and Mr. O’Leary’s individual objectives. If Mr. O’Leary is terminated without cause the Company will provide Mr. O’Leary as severance an amount equal to six (6) months of his base salary. Concurrently, the Company and Mr. O’Leary entered into a Non-Disclosure, Non-Solicitation and Non-Compete Agreement, effective as of September 20, 2022 that contains a non-solicitation and non-compete provision which will be in effect for a two-year period following the termination of Mr. O’Leary’s employment relationship with the Company; provided, however, such period is shortened to six (6) months if Mr. O’Leary is terminated without cause. During October 2022, the Company initiated a plan to sell the ACO/MSO Division, comprised of the operations of CHM and its subsidiary AHP, which were acquired by the Company on May 18, 2020. CHM and AHP operate an ACO that assists physician practices in providing coordinated and more efficient care to patients via the MSSP, as administered by the CMS, which rewards providers for efficiency in patient care. The Company expects to use the cash proceeds generated from a sale to supplement its operating cash requirements and pursue additional acquisitions. The Company expects to complete a sale by the first quarter of 2023. On October 21, 2022, the Company issued a promissory note payable to an investor in the principal amount of $144,760 (the “October 2022 Note”). The October 2022 Note had an original issue discount of $15,510 and fees of $4,250, resulting in net proceeds to the Company of $125,000. The October 2022 Note does not bear interest in excess of the original issue discount and matures on October 31, 2023. The Company is required to make 10 monthly payments of $16,213 starting November 30, 2022. On November 8, 2022, the Company entered into a Merchant Cash Advance (“MCA”) agreement with a trust controlled by the Company’s Chief Executive Officer, Dr. Michael Dent, pursuant to which the Company received an advance of $150,000. The Company is required to repay the MCA, which acts like a note payable, at the rate of $3,750 per week for 52 weeks. The MCA is guaranteed by the Company’s NCFM subsidiary.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2022
Business and Business Presentation [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP. All amounts referred to in the notes to the consolidated financial statements are in United States Dollars ($) unless stated otherwise.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about fair valuation of acquired intangible assets, cash flow and fair value assumptions associated with measurements of contingent acquisition consideration and impairment of intangible assets and goodwill, valuation of inventory, collection of accounts receivable, the valuation and recognition of stock-based compensation expense, valuation allowance for deferred tax assets, borrowing rate consideration for right-of-use (“ROU”) lease assets including related lease liability and useful life of fixed assets.
Revenue Recognition	Revenue Recognition Patient service revenue Patient service revenue is earned for GYN services provided to patients at our NWC facility, functional medicine services provided to patients at our NCFM facility, and physical therapy services provided to patients at our BTG facility. Patient service revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients and third-party payors (including health insurers and government programs) and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Company bills patients and third-party payors within days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time, which includes prepaid BTG physical therapy bundles for which performance obligations are satisfied over time as visits are incurred, is recognized based on actual charges incurred in relation to total expected charges. The Company believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Revenue for performance obligations satisfied at a point in time, which includes all patient service revenue other than BTG physical therapy bundles, is recognized when goods or services are provided at the time of the patient visit, and at which time the Company is not required to provide additional goods or services to the patient. The Company determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. Estimates of contractual adjustments and discounts require significant judgment and are based on the Company’s current contractual agreements, its discount policies, and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. There were no material changes during the nine months ended September 30, 2022 or 2021 to the judgments applied in determining the amount and timing of patient service revenue. Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows: ● Medicare: ● Medicaid: ● Other: Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Company estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Patient services provided by NCFM, BTG and AEU are provided on a cash basis and not submitted through third party insurance providers. Contract liabilities related to prepaid BTG patient service revenue were $23,015 and $42,530 as of September 30, 2022 and December 31, 2021, respectively. Medicare Shared Savings Revenue The Company earns Medicare shared savings revenue based on performance of the population of patient lives for which it is accountable as an ACO against benchmarks established by the MSSP. Because the MSSP, which was formed in 2012, is relatively new and has limited historical experience, the Company cannot accurately predict the amount of shared savings that will be determined by CMS. Such amounts are determined annually when the Company is notified by CMS of the amount of shared savings earned. Accordingly, the Company recognizes Medicare shared savings revenue in the period in which the CMS notifies the Company of the exact amount of shared savings to be paid, which historically has occurred during the fiscal quarter ended September 30 for the program year ended December 31 of the previous year. Based on the ACO operating agreements, the Company bears all costs of the ACO operations until revenue is recognized. At that point, the Company shares in up to 100% of the revenue to recover its costs incurred. Consulting and Event Revenue Also pursuant to ASC 606, the Company recognizes service revenue as services are provided, with any unearned but paid amounts recorded as a contract liability at each balance sheet date. Contract liabilities related to consulting revenue were $25,000 and $25,000 as of September 30, 2022 and December 31, 2021, respectively. Event revenue, comprised of admission fees for summit events, is recognized when an event is held. Product Revenue Revenue is derived from the distribution of medical products that are sourced from a third party. The Company recognizes revenue at a point in time when title transfers to customers and the Company has no further obligation to provide services related to such products, which occurs when the product ships. The Company is the principal in its revenue transactions and as a result revenue is recorded on a gross basis. The Company has determined that it controls the ability to direct the use of the product provided prior to transfer to a customer, is primarily responsible for fulfilling the promise to provide the product to its customer, has discretion in establishing prices, and ultimately controls the transfer of the product to the customer. Shipping and handling costs billed to customers are recorded in revenue. Contract liabilities related to product revenue were $17,237 and $5,308 as of September 30, 2022 and December 31, 2021, respectively. There were no contract assets as of September 30, 2022 or December 31, 2021. Sales are made inclusive of sales tax, where such sales tax is applicable. Sales tax is applicable on sales made in the state of Florida, where the Company has physical nexus. The Company has determined that it does not have economic nexus in any other states. The Company does not sell products outside of the United States. The Company maintains a return policy that allows customers to return a product within a specified period of time prior to and subsequent to the expiration date of the product. The Company analyzes the need for a product return allowance at the end of each period based on eligible products. Product return allowance was $5,643 and $14,834 as of September 30, 2022 and December 31, 2021, respectively. Contract Liabilities Contract liabilities represent payments from customers for consulting services, patient services and medical products that precede the Company’s service or product fulfillment performance obligation. The Company’s total contract liabilities balance were $65,252 and $72,838 as of September 30, 2022 and December 31, 2021, respectively. Provider shared savings expense Provider shared savings expense represents the ongoing operating expenses of the ACO and annual payments made to the ACO’s participating providers from shared savings revenue payments received from CMS (the “Annual Provider Payment”). The pool of funds available for the Annual Provider Payment, as well as the amounts paid to each individual participating provider from the pool, is determined by ACO management after an annual determination of Medicare shared savings revenue is made by CMS. Expenses related to ongoing operation of the ACO may be deducted from the Medicare shared savings revenue before determining the Annual Provider Payment. Such expenses are recognized in “Provider shared savings expense” as incurred. Expense related to the Annual Provider Payment is recognized in the period in which the size of the Annual Provider Payment pool is determined, which typically corresponds to the period in which the shared saving payment is received from CMS and shared savings revenue is recognized. This typically occurs in the second half of the year following the completion of the program year.
Cash and Cash Equivalents	Cash and Cash Equivalents For financial statement purposes, the Company considers all highly liquid investments with original maturities of six months or less to be cash and cash equivalents. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. As of September 30, 2022 and December 31, 2021, the Company had $-0- and $2,957,040 in excess of the FDIC insured limit, respectively.
Accounts Receivable	Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates 48% of total billings. Trade accounts receivable are recorded at this net amount. As of September 30, 2022 and December 31, 2021, the Company’s gross patient services accounts receivable were $84,905 and $193,363, respectively, and net patient services accounts receivable were $41,349 and $86,287, respectively, based upon net reporting of accounts receivable. The Company also had consulting services receivable of $22,506 and $-0- as of September 30, 2022 and December 31, 2021, respectively. As of September 30, 2022 and December 31, 2021, the Company’s allowance of doubtful accounts was $-0- and $13,972, respectively.
Leases	Leases Upon transition under ASU 2016-02, the Company elected the suite of practical expedients as a package applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. For new leases, the Company will determine if an arrangement is or contains a lease at inception. Leases are included as ROU assets within other assets and ROU liabilities within accrued expenses and other liabilities and within other long-term liabilities on the Company’s consolidated balance sheets. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s leases do not provide an implicit rate. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. See Note 8 for more complete details on balances as of the reporting periods presented herein.
Inventory	Inventory Inventory consisting of supplements, is stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method. Outdated inventory is directly charged to cost of goods sold.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill is recognized as the excess cost of an acquired entity over the net amount assigned to assets acquired and liabilities assumed. Goodwill is not amortized, but rather tested for impairment on an annual basis and more often if circumstances require. Impairment losses are recognized whenever the implied fair value of goodwill is less than its carrying value. The Company recognizes an acquired intangible apart from goodwill whenever the intangible arises from contractual or other legal rights, or whenever it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their estimated useful lives unless the estimated useful life is determined to be indefinite. Amortizable intangible assets are being amortized primarily over useful lives of five years. The straight-line method of amortization is used as it has been determined to approximate the use pattern of the assets. Impairment losses are recognized if the carrying amount of an intangible that is subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value. The Company also maintains intangible assets with indefinite lives, which are not amortized. These intangibles are tested for impairment on an annual basis and more often if circumstances require. Impairment losses are recognized whenever the implied fair value of these assets is less than their carrying value. No impairment charges were recognized in the three and nine months ended September 30, 2022 or 2021.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. The Company relies on a sole supplier for the fulfillment of substantially all of its product sales made through MOD.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.
Convertible Notes	Convertible Notes
Government Notes Payable	Government Notes Payable During 2020, the Company and certain of its subsidiaries received loans under the Paycheck Protection Program (the “PPP”). The PPP loans, administered by the U.S. Small Business Administration (the “SBA”), were issued under the Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES Act. Pursuant to the terms of the PPP, principal amounts may be forgiven if loan proceeds are used for qualifying expenses as described in the CARES Act, including costs such as payroll, benefits, employer payroll taxes, rent and utilities. The Company accounts for forgiveness of government loans pursuant to FASB ASC 470, “Debt,” (“ASC 470”). Pursuant to ASC 470, loan forgiveness is recognized in earnings as a gain on extinguishment of debt when the debt is legally released by the lender.
Fair Value of Assets and Liabilities	Fair Value of Assets and Liabilities Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs: ● Level 1 – ; ● Level 2 ● Level 3 The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a binomial lattice option pricing model to estimate the fair value of options, warrants, beneficial conversion features and other Level 3 financial assets and liabilities. The Company believes that the binomial lattice model results in the best estimate of fair value because it embodies all of the requisite assumptions (including the underlying price, exercise price, term, volatility, and risk-free interest-rate) necessary to fairly value these instruments and, unlike less sophisticated models like the Black-Scholes model, it also accommodates assumptions regarding investor exercise behavior and other market conditions that market participants would likely consider in negotiating the transfer of such an instruments.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation to employees and nonemployees under ASC 718 “Compensation – Stock Compensation” using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company uses a binomial lattice pricing model to estimate the fair value of options and warrants granted.
Income Taxes	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. No income tax has been provided for the three and nine months ended September 30, 2022 and 2021, since the Company has sustained a loss for both periods. Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, management has determined a full valuation allowance for the deferred tax assets, since it is more likely than not that the deferred tax assets will not be realizable.
Recurring Fair Value Measurements	Recurring Fair Value Measurements The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, short-term borrowings, accounts payable, accrued liabilities, and derivative financial instruments approximated their fair value.
Deemed Dividend	Deemed Dividend The Company incurs a deemed dividend on Series B Convertible Preferred Voting Stock (the “Series B Preferred”). As the intrinsic price per share of the Series B Preferred was less than the deemed fair value of the Company’s common stock on the date of issuance of the Series B Preferred, the Series B Preferred contains a beneficial conversion feature as described in FASB ASC 470-20, “Debt with Conversion and Other Options.” The difference in the stated conversion price and estimated fair value of the common stock is accounted for as a beneficial conversion feature and affects income or loss available to common stockholders for purposes of earnings per share available to common stockholders. The Company incurs further deemed dividends on certain of its warrants containing a down round provision equal to the difference in fair value of the warrants before and after the triggering of the down round adjustment.
Net Loss per Share	Net Loss per Share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the three and nine months ended September 30, 2022 and 2021, the Company reported a net loss and excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of September 30, 2022 and December 31, 2021, potentially dilutive securities were comprised of (i) 62,259,569 and 59,796,992 warrants outstanding, respectively, (ii) 3,999,250 and 3,456,250 stock options outstanding, respectively, (iii) 219,768 and 302,050 unissued shares subject to future vesting requirements granted pursuant to the Company’s Employee Incentive Plan, (iv) up to 1,329,469 common shares issuable that are earned but not paid under consulting and director compensation arrangements, and (v) up to 13,750,000 and 13,750,000 shares of common stock issuable upon conversion of Series B Preferred.
Common stock awards	Common stock awards The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded on the consolidated statement of comprehensive loss in the same manner and charged to the same account as if such settlements had been made in cash. From time to time, the Company also issues stock awards settleable in a variable number of common shares. Such awards are classified as liabilities until such time as the number of shares underlying the grant is determinable.
Warrants	Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes pricing model as of the measurement date. The Company uses a binomial lattice pricing model to estimate the fair value of compensation options and warrants. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period, or at the date of issuance, if there is not a service period. Certain of the Company’s warrants include a so-called down round provision. The Company accounts for such provisions pursuant to ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging
Business Segments	Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has four operating segments: Health Services (multi-specialty medical group including the NWC GYN practice, the NCFM functional medicine practice, the BTG physical therapy practice, and the AEU cosmetic services practice), Digital Healthcare (develops and markets the “HealthLynked Network,” an online personal medical information and record archive system), ACO/MSO (comprised of the ACO/MSO business acquired with CHM in May 2020, which assists physician practices in providing coordinated and more efficient care to patients via the MSSP), and Medical Distribution (comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices).
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments”: The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. The Company is currently evaluating the impact the adoption of this guidance may have on its consolidated financial statements. In August 2020, the FASB issued ASU 2020-06 Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) In October 2021, the FASB issued guidance which requires companies to apply Topic 606, Revenue from Contracts with Customers
Recently Adopted Pronouncements	Recently Adopted Pronouncements In December 2019, the FASB issued ASU 2019-12 Simplifying the Accounting for Income Taxes In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The ASU provides guidance to clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. ASU 2021-04 is effective for annual periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements. The Company adopted this standard for the year ended December 31, 2022. The adoption did not have a material effect on the Company’s consolidated financial statements. No other new accounting pronouncements were issued or became effective in the period that had, or are expected to have, a material impact on our consolidated Financial Statements.

Acquisition (Tables)

Acquisition (Tables)	9 Months Ended
	Sep. 30, 2022
Acquisition [Abstract]
Schedule of summarizes the fair value	Fair value of shares issued at closing $ 103,804 Cash consideration 139,923 Payment of AEU debt obligations in cash 185,077 Less cash received (11,198 ) Total Fair Value of Consideration Paid $ 417,606
Schedule of assets acquired and liabilities	Inventory $ 13,272 Fixed assets 152,759 Right of use lease asset 80,264 Accounts payable and accruals (33,037 ) Loans payable (35,346 ) Lease liability (80,264 ) Fair Value of Identifiable Assets Acquired and Liabilities Assumed $ 97,648
Schedule of income statement	Nine Months Ended 2022 2021 Revenue $ 4,919,274 $ 5,245,035 Net loss $ (4,455,431 ) $ (8,568,344 )

Prepaid Expenses and Other (Tab

Prepaid Expenses and Other (Tables)	9 Months Ended
	Sep. 30, 2022
Prepaid Expenses and Other Current Assets Table [Abstract]
Schedule of prepaid and other expenses	September 30, December 31, 2022 2021 Insurance prepayments $ 20,899 $ 25,020 Other expense prepayments 30,910 50,860 Rent deposits 44,125 49,125 Deferred equity compensation 83,125 151,250 Total prepaid expenses and other 179,059 276,255 Less: long term portion (84,091 ) (138,625 ) Prepaid expenses and other, current portion $ 94,968 $ 137,630

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	September 30, December 31, 2022 2021 Medical equipment $ 493,854 $ 484,126 Furniture, office equipment and leasehold improvements 316,463 149,868 Total property, plant and equipment 810,317 633,994 Less: accumulated depreciation (368,985 ) (283,512 ) Property, plant and equipment, net $ 441,332 $ 350,482

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	September 30, December 31, 2022 2021 NCFM: Medical database $ 1,101,538 $ 1,101,538 NCFM: Website 41,000 41,000 CHM: ACO physician contracts 1,073,000 1,073,000 MOD: Website 3,538,000 3,538,000 Total intangible assets 5,753,538 5,753,538 Less: accumulated amortization (1,410,250 ) (873,417 ) Intangible assets, net $ 4,343,288 $ 4,880,121
Schedule of goodwill	September 30, December 31, 2022 2021 CHM $ 381,856 $ 381,856 MOD 766,249 766,249 AEU 319,958 --- Goodwill $ 1,468,063 $ 1,148,105

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases (Tables) [Line Items]
Schedule of lease-related assets and liabilities	September 30, December 31, 2022 2021 Lease assets $ 636,267 $ 526,730 Lease liabilities Lease liabilities (short term) $ 378,759 $ 288,966 Lease liabilities (long term) 259,845 239,225 Total lease liabilities $ 638,604 $ 528,191
Schedule of maturities of operating lease liabilities	2022 (October to December) $ 119,116 2023 396,833 2024 126,116 2025 74,729 2026 18,148 2027 990 Total lease payments 735,932 Less interest (97,328 ) Present value of lease liabilities $ 638,604

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Schedule of accounts payable and accrued expenses	September 30, December 31, 2022 2021 Trade accounts payable $ 649,185 $ 306,220 Accrued payroll liabilities 94,106 172,500 Accrued operating expenses 391,653 265,411 Accrued interest 59,349 46,712 $ 1,194,293 $ 790,843

Contract Liabilities (Tables)

Contract Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Contract Liabilities Table [Abstract]
Schedule of amounts related to contract liabilities	September 30, December 31, 2022 2021 Patient services paid but not provided $ 23,015 $ 42,530 Consulting services paid but not provided 25,000 25,000 Unshipped products 17,237 5,308 $ 65,252 $ 72,838

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of notes payable	September 30, December 31, 2022 2021 SBA Disaster relief loans $ 450,000 $ 450,000 Promissory note payable to SEPA investor 411,405 --- AEU note payable 7,343 --- Face value of notes payable 868,748 450,000 Less: unamortized discount (20,879 ) --- Notes payable, total 847,869 450,000 Less: long term portion (450,000 ) (450,000 ) Notes payable, current portion $ 397,869 $ ---

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Shareholders' Equity (Tables) [Line Items]
Schedule of common stock issuable	September 30, 2022 December 31, 2021 Amount Shares Amount Shares Shares issuable to consultants, employees and directors $ 345,345 1,329,469 $ 282,347 719,366
Schedule of stock warrants	2022 2021 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 59,796,992 $ 0.25 51,352,986 $ 0.17 Granted during the period 3,249,244 $ 0.17 22,421,026 $ 0.39 Exercised during the period --- $ --- (13,637,020 ) $ (0.18 ) Expired during the period (786,667 ) $ (0.44 ) --- $ --- Outstanding at end of the period 62,259,569 $ 0.24 60,136,992 $ 0.25 Exercisable at end of the period 62,259,569 $ 0.24 60,136,992 $ 0.25 Weighted average remaining life 2.6 years 3.4 years
Schedule of fair value of the warrants	2022 2021 Pricing model utilized Binomial Lattice Binomial Lattice Risk free rate range 2.94% 0.38% to 0.97% Expected life range (in years) 5.00 years 3.00 to 5.00 years Volatility range 74.50% 170.58% to 193.21% Dividend yield 0.00% 0.00%
Schedule of financial statements with respect to the EIPs	2022 2021 Total cost of share-based payment plans during the period $ 335,860 $ 574,998 Amounts capitalized in deferred equity compensation during period $ --- $ --- Amounts charged against income for amounts previously capitalized $ (9,375 ) $ --- Amounts charged against income, before income tax benefit $ 326,485 $ 574,998 Amount of related income tax benefit recognized in income $ --- $ ---
Schedule of fair value of options granted	2022 2021 Pricing model utilized Binomial Lattice Binomial Lattice Risk free rate range 2.81% to 2.90% 1.47% to 2.90% Expected life range (in years) 10.00 years 10.00 years Volatility range 74.38% to 74.50% 74.38% to 192.25% Dividend yield 0.00% 0.00%
Employee Equity Incentive Plan [Member]
Shareholders' Equity (Tables) [Line Items]
Schedule of stock option activity	2022 2021 Weighted Weighted Average Average Exercise Exercise Stock options Number Price Number Price Outstanding at beginning of period 3,456,250 $ 0.23 3,111,750 $ 0.20 Granted during the period 975,000 $ 0.16 80,000 $ 0.75 Exercised during the period (12,500 ) $ (0.26 ) (145,500 ) $ (0.11 ) Forfeited during the period (419,500 ) $ (0.31 ) (32,500 ) $ (0.16 ) Outstanding at end of period 3,999,250 $ 0.20 3,013,750 $ 0.22 Options exercisable at period-end 2,655,500 $ 0.20 2,173,750 $ 0.19
Schedule of stock grant activity	2022 2021 Weighted Weighted Average Average Grant Date Grant Date Stock Grants Shares Fair Value Shares Fair Value Nonvested grants at beginning of period 302,050 $ 0.27 200,000 $ 0.17 Granted 377,454 $ 0.17 1,015,047 $ 0.27 Vested (354,782 ) $ (0.23 ) (1,075,047 ) $ (0.26 ) Forfeited (104,954 ) $ (0.19 ) (50,000 ) $ (0.10 ) Nonvested grants at end of period 219,768 $ 0.20 90,000 $ 0.19
Employee Stock [Member]
Shareholders' Equity (Tables) [Line Items]
Schedule of non-vested options issued	2022 2021 Weighted Weighted Average Average Grant Date Grant Date Stock options Shares Fair Value Shares Fair Value Nonvested options at beginning of period 858,750 $ 0.23 1,044,375 $ 0.21 Granted 975,000 $ 0.09 80,000 $ 0.62 Vested (195,750 ) $ (0.22 ) (255,000 ) $ (0.25 ) Forfeited (294,250 ) $ (0.26 ) (29,375 ) $ (0.12 ) Nonvested options at end of period 1,343,750 $ 0.12 840,000 $ 0.24
Warrant [Member]
Shareholders' Equity (Tables) [Line Items]
Schedule of stock option activity	Warrants Outstanding Warrants Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.0001 to 0.09 14,789,573 2.3 $ 0.07 14,789,573 $ 0.07 $ 0.10 to 0.24 12,690,290 2.7 $ 0.17 12,690,290 $ 0.17 $ 0.25 to 0.49 31,319,782 2.6 $ 0.31 31,319,782 $ 0.31 $ 0.50 to 1.05 3,459,924 3.8 $ 0.69 3,459,924 $ 0.69 $ 0.05 to 1.00 62,259,569 2.6 $ 0.24 62,259,569 $ 0.24

Contingent Acquisition Consid_2

Contingent Acquisition Consideration (Tables)	9 Months Ended
	Sep. 30, 2022
Contingent Acquisition Consideration Table [Abstract]
Schedule of fair value of contingent acquisition	September 30, December 31, 2022 2021 Fair value of HCFM contingent acquisition consideration $ --- $ 172,124 Fair value of CHM contingent acquisition consideration 218,236 276,529 Fair value of MOD contingent acquisition consideration 94,497 737,037 Total contingent acquisition consideration 312,733 1,185,690 Less: long term portion (184,659 ) (782,224 ) Contingent acquisition consideration, current portion $ 128,074 $ 403,466
Schedule of gains (losses) on the change in the fair value of contingent acquisition	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 HCFM contingent acquisition consideration $ --- $ (14,316 ) $ (35,259 ) $ (63,769 ) CHM contingent acquisition consideration 62,516 (116,150 ) 58,292 (54,848 ) MOD contingent acquisition consideration 70,967 256,877 642,540 (116,061 ) $ 133,483 $ 126,411 $ 665,573 $ (234,678 )
Schedule of maturities of contingent acquisition consideration	2022 (October to December) $ 92,546 2023 85,169 2024 135,018 $ 312,733

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of maturities operating lease liabilities	2022 (October to December) $ 119,116 2023 396,833 2024 126,116 2025 74,729 2026 18,148 2027 990 Total lease payments 735,932 Less interest (97,328 ) Present value of lease liabilities $ 638,604

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Schedule of segment information	Three Months Ended September 30, 2022 Health Services Digital Healthcare ACO / MSO Medical Distribution Total Revenue Patient service revenue, net $ 1,262,253 $ --- $ --- $ --- $ 1,262,253 Subscription, consulting and event revenue --- 1,171 88,806 --- 89,977 Product revenue --- --- --- 95,449 95,449 Total revenue 1,262,253 1,171 88,806 95,449 1,447,679 Operating Expenses Practice salaries and benefits 810,058 --- --- --- 810,058 Other practice operating expenses 695,300 --- --- --- 695,300 Medicare shared savings expenses --- --- 337,533 --- 337,533 Cost of product revenue --- --- --- 87,775 87,775 Selling, general and administrative expenses --- 1,055,178 --- 32,955 1,088,133 Depreciation and amortization 31,198 1,406 --- 176,900 209,504 Total Operating Expenses 1,536,556 1,056,584 337,533 297,630 3,228,303 (Loss) income from operations $ (274,303 ) $ (1,055,413 ) $ (248,727 ) $ (202,181 ) $ (1,780,624 ) Other Segment Information Interest expense (income) $ 2,815 $ 2,825 $ --- $ --- $ 5,640 Financing cost $ 110,000 $ --- $ --- $ --- $ 110,000 Amortization of original issue discounts on notes payable $ 18,480 $ 2,540 $ --- $ --- $ 21,020 Change in fair value of contingent acquisition consideration $ --- $ (133,483 ) $ --- $ --- $ (133,483 ) Nine Months Ended September 30, 2022 Health Services Digital Healthcare ACO / MSO Medical Distribution Total Revenue Patient service revenue, net $ 4,069,714 $ --- $ --- $ --- $ 4,069,714 Subscription, consulting and event revenue --- 9,433 251,058 --- 260,491 Product revenue --- --- --- 372,877 372,877 Total revenue 4,069,714 9,433 251,058 372,877 4,703,082 Operating Expenses Practice salaries and benefits 2,344,529 --- --- --- 2,344,529 Other practice operating expenses 1,897,070 --- --- --- 1,897,070 Medicare shared savings expenses --- --- 802,411 --- 802,411 Cost of product revenue --- --- --- 419,129 419,129 Selling, general and administrative expenses --- 3,529,289 --- 149,495 3,678,784 Depreciation and amortization 87,134 4,472 --- 530,700 622,306 Total Operating Expenses 4,328,733 3,533,761 802,411 1,099,324 9,764,229 Income (loss) from operations $ (259,019 ) $ (3,524,328 ) $ (551,353 ) $ (726,447 ) $ (5,061,147 ) Other Segment Information Interest expense (income) $ 8,420 $ 6,731 $ --- $ --- $ 15,151 Financing cost $ 110,000 $ --- $ --- $ --- $ 110,000 Amortization of original issue discounts on notes payable $ 18,480 $ 2,540 $ --- $ --- $ 21,020 Change in fair value of contingent acquisition consideration $ --- $ (665,573 ) $ --- $ --- $ (665,573 ) September 30, 2022 Identifiable assets $ 2,182,272 $ 507,030 $ 1,132,696 $ 2,188,509 $ 6,010,507 Goodwill $ 319,958 $ --- $ 381,856 $ 766,249 $ 1,468,063 December 31, 2021 Identifiable assets $ 2,152,533 $ 3,450,332 $ 1,167,965 $ 2,775,621 $ 9,546,451 Goodwill $ --- $ --- $ 381,856 $ 766,249 $ 1,148,105 Three Months Ended September 30, 2021 Health Services Digital Healthcare ACO / MSO Medical Distribution Total Revenue Patient service revenue, net $ 1,394,356 $ --- $ --- $ --- $ 1,394,356 Medicare shared savings revenue --- --- 2,419,312 --- 2,419,312 Subscription, consulting and event revenue --- --- 69,595 --- 69,595 Product revenue --- --- --- 161,456 161,456 Total revenue 1,394,356 --- 2,488,907 161,456 4,044,719 Operating Expenses Practice salaries and benefits 739,024 --- --- --- 739,024 Other practice operating expenses 549,086 --- --- --- 549,086 Medicare shared savings expenses --- --- 1,748,585 --- 1,748,585 Cost of product revenue --- --- --- 145,432 145,432 Selling, general and administrative expenses --- 1,093,461 --- 54,130 1,147,591 Depreciation and amortization 26,196 2,215 --- 176,900 205,311 Total Operating Expenses 1,314,306 1,095,676 1,748,585 376,462 4,535,029 Loss from operations $ 80,050 $ (1,095,676 ) $ 740,322 $ (215,006 ) $ (490,310 ) Other Segment Information Interest expense (income) $ 2,706 $ 1,412 $ --- $ --- $ 4,118 Change in fair value of contingent acquisition consideration $ --- $ (126,411 ) $ --- $ --- (126,411 ) Nine Months Ended September 30, 2021 Health Digital ACO / Medical Total Revenue Patient service revenue, net $ 4,379,282 $ --- $ --- $ --- $ 4,379,282 Medicare shared savings revenue --- --- 2,419,312 --- 2,419,312 Subscription, consulting and event revenue --- 11,905 217,209 --- 229,114 Product revenue --- --- --- 512,325 512,325 Total revenue 4,379,282 11,905 2,636,521 512,325 7,540,033 Operating Expenses Practice salaries and benefits 2,305,993 --- --- --- 2,305,993 Other practice operating expenses 1,790,874 --- --- --- 1,790,874 Medicare shared savings expenses --- --- 2,157,555 --- 2,157,555 Cost of product revenue --- --- --- 474,026 474,026 Selling, general and administrative expenses --- 3,472,493 --- 188,713 3,661,206 Depreciation and amortization 83,493 3,405 --- 536,540 623,438 Total Operating Expenses 4,180,360 3,475,898 2,157,555 1,199,279 11,013,092 Income (loss) from operations $ 198,922 $ (3,463,993 ) $ 478,966 $ (686,954 ) $ (3,473,059 ) Other Segment Information Interest expense (income) $ 5,145 $ 8,038 $ --- $ (100 ) $ 13,083 (Gain) loss on extinguishment of debt $ (502,959 ) $ 5,471,884 $ --- $ (11,757 ) $ 4,957,168 Change in fair value of debt $ --- $ 19,246 $ --- $ --- $ 19,246 Change in fair value of contingent acquisition consideration $ --- $ 234,678 $ --- $ --- $ 234,678 September 30, 2021 Identifiable assets $ 2,104,819 $ 3,967,850 $ 2,850,949 $ 2,890,389 $ 11,814,007 Goodwill $ --- $ --- $ 381,856 $ 766,249 $ 1,148,105

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of fair value measurements	As of September 30, 2022 As of December 31, 2021 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Liability-classified equity instruments $ --- $ --- $ 83,125 $ 83,125 $ --- $ --- $ 162,500 $ 162,500 Contingent acquisition consideration --- --- 312,733 312,733 --- --- 1,185,690 1,185,690 Total $ --- $ --- $ 395,858 $ 395,858 $ --- $ --- $ 1,348,190 $ 1,348,190
Schedule of level 3 financial instruments measured at fair value on recurring basis	Three Months Ended Nine Months Ended 2022 2021 2022 2021 Convertible notes payable $ --- $ --- $ --- $ (19,246 ) Contingent acquisition consideration 133,483 126,411 665,573 (234,678 ) Total $ 133,483 $ 126,411 $ 665,573 $ (253,924 )

Business and Business Present_2

Business and Business Presentation (Details) - shares	Feb. 05, 2018	Sep. 02, 2014
Business and Business Presentation [Abstract]
Number of authorized shares		250,000,000
Shares of common stock		230,000,000
Shares of preferred stock		20,000,000
Increase authorized shares of common stock	500,000,000

Significant Accounting Polici_2

Significant Accounting Policies (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Significant Accounting Policies (Details) [Line Items]
Contract liabilities	$ 65,252	$ 72,838
Shares revenue percentage	100%
Product return allowance	$ 5,643	14,834
FDIC insurance amount	250,000
Insured excess	$ 0	2,957,040
Percentage of customers accounts receivable billings	48%
Accounts receivable net	$ 84,905	193,363
Net patient services accounts receivable	41,349	86,287
Consulting services receivable	22,506	0
Allowance of doubtful accounts	$ 0	$ 13,972
Concentration risk percentage	10%
Warrant [Member]
Significant Accounting Policies (Details) [Line Items]
Anti-dilutive securities (in Shares)	62,259,569	59,796,992
Unissued [Member]
Significant Accounting Policies (Details) [Line Items]
Anti-dilutive securities (in Shares)	219,768	302,050
Common Stock Issuable [Member]
Significant Accounting Policies (Details) [Line Items]
Anti-dilutive securities (in Shares)	1,329,469	1,329,469
Minimum [Member]
Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	5 years
Maximum [Member]
Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	7 years
Stock Options [Member]
Significant Accounting Policies (Details) [Line Items]
Anti-dilutive securities (in Shares)	3,999,250	3,456,250
Product revenue [Member]
Significant Accounting Policies (Details) [Line Items]
Contract liabilities	$ 17,237	$ 5,308
BTG patient service revenue [Member]
Significant Accounting Policies (Details) [Line Items]
Contract liabilities	23,015	42,530
Consulting revenue [Member]
Significant Accounting Policies (Details) [Line Items]
Contract liabilities	$ 25,000	$ 25,000
Series B Preferred Stock [Member] | Common Stock Issuable [Member]
Significant Accounting Policies (Details) [Line Items]
Anti-dilutive securities (in Shares)	13,750,000	13,750,000

Liquidity and Going Concern A_2

Liquidity and Going Concern Analysis (Details) - USD ($)			3 Months Ended	9 Months Ended
	Oct. 21, 2022	Jul. 05, 2022	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Jul. 19, 2022	Dec. 31, 2021
Liquidity and Going Concern Analysis (Details) [Line Items]
Cash			$ 158,160	$ 158,160		$ 561,000
Working capital deficit				1,989,943
Accumulated deficit			(36,746,934)	(36,746,934)			$ (32,205,189)
Net loss				4,541,745
Net cash used by operating activities				(3,762,644)	$ (1,627,184)
Net cash used by financing activities				1,173,908	$ 7,248,372
Common stock, par value (in Dollars per share)		$ 0.0001
Proceeds amount	$ 125,000
Proceeds sale amount			125,618	125,618
Initial principal amount						$ 550,000
Payment of promissory note			149,595
Unpaid principal				411,405
Common Stock [Member]
Liquidity and Going Concern Analysis (Details) [Line Items]
Shares of common stock (in Shares)		30,000,000
Proceeds sale amount			125,618	$ 125,618
Sepa [Member]
Liquidity and Going Concern Analysis (Details) [Line Items]
Proceeds amount			$ 297,405
Shares issued (in Shares)			2,708,100	2,708,100

Acquisition (Details)

Acquisition (Details)	9 Months Ended
	Sep. 30, 2022 USD ($)
Acquisition [Abstract]
Terms of acquisition, description	Under the terms of acquisition, the Company paid AEU equity holders consideration of (i) $139,923 cash (less $11,198 cash on hand at AEU as of the closing date), (ii) payment in cash of direct financial obligation of AEU on, or in close proximity to, the date of the business combination, in the amount of $185,077, and (iii) 792,394 shares of Company common stock at closing with a fair value of $103,804 determined using the average closing price of the Company’s common shares for the five days preceding the acquisition date. The total consideration fair value represents a transaction value of $417,606.
Goodwill	$ 319,958

Acquisition (Details) - Schedul

Acquisition (Details) - Schedule of summarizes the fair value	9 Months Ended
	Sep. 30, 2022 USD ($)
Schedule of Summarizes The Fair Value [Abstract]
Fair value of shares issued at closing	$ 103,804
Cash consideration	139,923
Payment of AEU debt obligations in cash	185,077
Less cash received	(11,198)
Total Fair Value of Consideration Paid	$ 417,606

Acquisition (Details) - Sched_2

Acquisition (Details) - Schedule of assets acquired and liabilities	Sep. 30, 2022 USD ($)
Schedule of Assets Acquired And Liabilities [Abstract]
Inventory	$ 13,272
Fixed assets	152,759
Right of use lease asset	80,264
Accounts payable and accruals	(33,037)
Loans payable	(35,346)
Lease liability	(80,264)
Fair Value of Identifiable Assets Acquired and Liabilities Assumed	$ 97,648

Acquisition (Details) - Sched_3

Acquisition (Details) - Schedule of income statement - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Schedule of Income Statement [Abstract]
Revenue	$ 4,919,274	$ 5,245,035
Net loss	$ (4,455,431)	$ (8,568,344)

Prepaid Expenses and Other (Det

Prepaid Expenses and Other (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Prepaid Expenses and Other Current Assets [Abstract]
Equity compensation	$ 255,000		$ 255,000
Amortization	$ 1,359	$ 0	$ 19,484	$ 0

Prepaid Expenses and Other (D_2

Prepaid Expenses and Other (Details) - Schedule of prepaid and other expenses - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Schedule of Prepaid and Other Expenses [Abstract]
Insurance prepayments	$ 20,899	$ 25,020
Other expense prepayments	30,910	50,860
Rent deposits	44,125	49,125
Deferred equity compensation	83,125	151,250
Total prepaid expenses and other	179,059	276,255
Less: long term portion	(84,091)	(138,625)
Prepaid expenses and other, current portion	$ 94,968	$ 137,630

Property, Plant, and Equipmen_2

Property, Plant, and Equipment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Member]
Property, Plant, and Equipment (Details) [Line Items]
Depreciation expense	$ 30,537	$ 26,343	$ 85,473	$ 80,764

Property, Plant, and Equipmen_3

Property, Plant, and Equipment (Details) - Schedule of property, plant and equipment - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 810,317	$ 633,994
Less: accumulated depreciation	(368,985)	(283,512)
Property, plant and equipment, net	441,332	350,482
Medical equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	493,854	484,126
Furniture, office equipment and leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 316,463	$ 149,868

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details) - USD ($)	3 Months Ended		9 Months Ended	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Estimated useful life			5 years
Amortization expense	$ 178,967	$ 178,968	$ 536,833	$ 542,674

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill (Details) - Schedule of intangible assets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	$ 5,753,538	$ 5,753,538
Less: accumulated amortization	(1,410,250)	(873,417)
Intangible assets, net	4,343,288	4,880,121
NCFM: Medical database [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	1,101,538	1,101,538
NCFM: Website [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	41,000	41,000
CHM: ACO physician contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	1,073,000	1,073,000
MOD: Website [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	$ 3,538,000	$ 3,538,000

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill (Details) - Schedule of goodwill - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Goodwill [Line Items]
Goodwill	$ 1,468,063	$ 1,148,105
CHM [Member]
Goodwill [Line Items]
Goodwill	381,856	381,856
MOD [Member]
Goodwill [Line Items]
Goodwill	766,249	766,249
AEU [Member]
Goodwill [Line Items]
Goodwill	$ 319,958

Leases (Details)

Leases (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating leases, description			The Company has separate operating leases for office space related to its NWC, NCFM, BTG and AEU practices, two separate leases relating to its corporate headquarters, and a copier lease that expire in July 2023, May 2025, March 2023, March 2026, November 2023, November 2023 and January 2027, respectively.
Finance leases, description			As of September 30, 2022, the Company’s weighted-average remaining lease term relating to its operating leases was 2.1 years, with a weighted-average discount rate of 11.36%.
Lease expense	$ 123,069	$ 99,544	$ 31,814	$ 241,909

Leases (Details) - Schedule of

Leases (Details) - Schedule of lease-related assets and liabilities - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Schedule of Lease Related Assets And Liabilities [Abstract]
Lease assets	$ 636,267	$ 526,730
Lease liabilities
Lease liabilities (short term)	378,759	288,966
Lease liabilities (long term)	259,845	239,225
Total lease liabilities	$ 638,604	$ 528,191

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of maturities of operating lease liabilities - Operating Leases [Member]	Sep. 30, 2022 USD ($)
Leases (Details) - Schedule of maturities of operating lease liabilities [Line Items]
2022 (October to December)	$ 119,116
2023	396,833
2024	126,116
2025	74,729
2026	18,148
2027	990
Total lease payments	735,932
Less interest	(97,328)
Present value of lease liabilities	$ 638,604

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - Schedule of accounts payable and accrued expenses - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Accounts Payable And Accrued Expenses Abstract
Trade accounts payable	$ 649,185	$ 306,220
Accrued payroll liabilities	94,106	172,500
Accrued operating expenses	391,653	265,411
Accrued interest	59,349	46,712
Total	$ 1,194,293	$ 790,843

Contract Liabilities (Details)

Contract Liabilities (Details) - Schedule of amounts related to contract liabilities - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Contract Liabilities (Details) - Schedule of amounts related to contract liabilities [Line Items]
Contract liabilities	$ 65,252	$ 72,838
Patient services paid but not provided [Member]
Contract Liabilities (Details) - Schedule of amounts related to contract liabilities [Line Items]
Contract liabilities	23,015	42,530
Consulting services paid but not provided [Member]
Contract Liabilities (Details) - Schedule of amounts related to contract liabilities [Line Items]
Contract liabilities	25,000	25,000
Unshipped products [Member]
Contract Liabilities (Details) - Schedule of amounts related to contract liabilities [Line Items]
Contract liabilities	$ 17,237	$ 5,308

Amounts Due to Related Party _2

Amounts Due to Related Party and Related Party Transactions (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Dr. Michael Dent [Member]
Amounts Due to Related Party and Related Party Transactions (Details) [Line Items]
Deferred compensation	$ 300,600		$ 300,600		$ 300,600
Dr. Dent’s Spouse [Member]
Amounts Due to Related Party and Related Party Transactions (Details) [Line Items]
Consulting agreement amount	$ 39,038	$ 33,462	$ 100,385	$ 111,731

Notes Payable (Details)

Notes Payable (Details) - USD ($)				1 Months Ended		3 Months Ended		9 Months Ended
	Oct. 21, 2022	Jan. 14, 2021	Jan. 06, 2021	Jul. 19, 2022	May 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	May 31, 2021	Aug. 31, 2020	Jul. 31, 2020	Jun. 30, 2020	May 31, 2020	Apr. 03, 2020
Notes Payable (Details) [Line Items]
Recognized gain amount									$ 632,826
Interest income									6,503
Disaster relief loans						$ 450,000		$ 450,000		$ 450,000
Maturity term												30 years
Principal amount				$ 550,000
Original issue discount percentage				5%
Interest rate percentage				0%
Repaid cash premium percentage				2%
Total cash repayments				$ 561,000		158,160		158,160
Net proceeds	$ 125,000
Amortization expense						18,480		18,480
Cash payments						149,595		149,595
Proceeds of sales								125,618
Unpaid principal						411,405		411,405
Unamortized discount						20,020		$ 20,020
Promissory and other notes payable								the May 13, 2022 acquisition of AEU, the Company acquired (i) a bank note payable with a remaining principal balance of $9,689 that was repaid in full during July 2022, and (ii) a note payable to a third-party lender (the “AEU Note”) with a remaining principal balance of $29,057, an original issue discount of $3,400, and a net carrying value of $25,657. Amortization expense related to the AEU Note discount was $2,540 in each of the three and nine months ended September 30, 2022. During the three and nine months ended September 30, 2022, the Company made payments of $14,340 and $21,713, respectively, against the Promissory Note. The unpaid principal balance was $7,343 and the unamortized discount balance was $859 as of September 30, 2022.
Recognized a loss on debt extinguishment									5,463,492
Changes in fair value						0	$ 0	$ 0	19,246
Interest expense on convertible notes outstanding							0		4,372
Maximum [Member]
Notes Payable (Details) [Line Items]
Net proceeds				522,500
Minimum [Member]
Notes Payable (Details) [Line Items]
Net proceeds				$ 38,500
Subsidiaries [Member]
Notes Payable (Details) [Line Items]
Disaster relief loans												$ 450,000	$ 450,000	$ 450,000
Loans interest rate												3.75%	3.75%	3.75%
Loans [Member]
Notes Payable (Details) [Line Items]
Principal amount											$ 632,826			$ 621,069	$ 621,069	$ 11,757
Maturity date, description								The loans bore interest at 1% per annum and were scheduled to mature in May and June 2022.
Accrued interest					$ 6,503
Accrued on government and vendor notes payable						37,359		$ 37,359		$ 24,723
Interest expense						$ 4,252	$ 4,226	$ 12,636	$ 12,594
Extension and Conversion – January 2021 [Member]
Notes Payable (Details) [Line Items]
Debt instrument description		On January 14, 2021, the Company and the holder of the Extended Notes entered into a series of agreements pursuant to which (i) the holder agreed to convert the full face value of $1,038,500 and $317,096 of accrued interest on the Extended Notes into 13,538,494 shares of common stock pursuant to the original conversion terms of the underlying notes, (ii) the holder agreed to a 180-day leak out provision, whereby, from and after January 14, 2021, it may not sell shares of the Company’s common stock in excess of 5% of the Company’s daily trading volume for the first 90 days and 10% of the Company’s daily volume for the next 90 days, subject to certain exceptions, (iii) the holder agreed to release all security interests and share reserves related to the Extended Notes, and (iv) the Company issued to the holder a new five-year warrant to purchase 13,538,494 shares of common stock at an exercise price of $0.30 per share.	On January 6, 2021, the holder of four fixed rate convertible promissory notes with a face value of $1,038,500 – comprised of a $550,000 6% fixed convertible secured promissory note dated July 7, 2016 (the “$550k Note”), a $50,000 10% fixed convertible commitment fee promissory note dated July 7, 2016 (the “$50k Note”), $81,000 of principal remaining on a $111,000 10% fixed convertible secured promissory note dated May 22, 2017 (the “$111k Note”), and a $357,500 10% fixed convertible note dated April 15, 2019 (the “$357.5k Note” and together with the $550k Note, the $50k Note and the $111k Note, the “Extended Notes”) – agreed to extend the maturity date on the Extended Notes to January 14, 2021. In exchange for the extension, the Company agreed to extend the expiration date of 3,508,333 existing warrants held by the holder (the “Extended Warrants”) from dates between July 2021 and March 2022 until March 2023. Because the fair value of consideration issued was greater than 10% of the present value of the remaining cash flows under the modified Extended Notes, the transaction was treated as a debt extinguishment and reissuance of new debt instruments pursuant to the guidance of ASC 470-50. A loss on debt extinguishment was recorded in the amount of $126,502 in the nine months ended September 30, 2021, equal to the incremental fair value of the Extended Warrants before and after the modification.

Notes Payable (Details) - Sche

Notes Payable (Details) - Schedule of notes payable - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Schedule of Notes Payable [Abstract]
SBA Disaster relief loans	$ 450,000	$ 450,000
Promissory note payable to SEPA investor	411,405
AEU note payable	7,343
Face value of notes payable	868,748	450,000
Less: unamortized discount	(20,879)
Notes payable, total	847,869	450,000
Less: long term portion	(450,000)	(450,000)
Notes payable, current portion	$ 397,869

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 05, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Sep. 09, 2021	Jan. 01, 2016
Shareholders' Equity (Details) [Line Items]
SEPA advances descriptions	the obligation, to sell to Yorkville up to 30,000,000 of its shares of common stock, par value $0.0001 per share, at the Company’s request any time during the commitment period commencing on July 5, 2022 and terminating on the earliest of (i) the first day of the month following the 36-month anniversary of the SEPA and (ii) the date on which Yorkville shall have made payment of any advances requested pursuant to the SEPA for shares of the Company’s common stock equal to the commitment amount of 30,000,000 shares of common stock. Each SEPA Advance may be for a number of shares of common stock with an aggregate value of up to greater of: (i) an amount equal to thirty percent (30%) of the aggregate daily volume traded of the Company’s common stock for the three (3) trading days immediately preceding notice from the Company of an Advance, or (ii) 2,000,000 shares of common stock. The shares would be purchased at 96.0% of the average of the daily volume weighted average price of the Company’s common stock as reported by Bloomberg L.P. during regular trading hours during each of the three consecutive trading days commencing on the trading day following the Company’s submission of an Advance notice to Yorkville and would be subject to certain limitations, including that Yorkville could not purchase any shares that would result in it owning more than 4.99% of the Company’s outstanding common stock at the time of an Advance. On July 11, 2022, the Company filed a Form S-1 registration statement registering up to 30,000,000 shares of common stock underlying the SEPA. The registration statement was declared effective on July 19, 2022.
Diligence fees				$ 10,000
stock issued (in Shares)		895,255		895,255
Commitment fee		$ 100,000		$ 100,000
Other expenses		110,000	$ 110,000	110,000	$ 110,000
Proceed amount		$ 125,618		$ 297,405
Issuance of common stock (in Shares)		2,708,100		2,708,100
Investment agreement			3,000,000		$ 3,000,000
Issued common stock to consultant (in Shares)				305,524	677,242
Issuance of common stock (in Shares)								20,000,000
Total unrecognized compensation cost		$ 22,538		$ 22,538
Weighted-average period				1 year 1 month 6 days
Aggregate fair value of share grants		44.82	270,918	$ 44.82	$ 270,918
Weighted-average grant-date fair value of option grants (in Dollars per share)				$ 0.09	$ 0.62
Stock options exercised (in Shares)				12,500	145,500
Exercise amount					$ 16,450
Liability-Classified Equity Instruments description						The original grant date fair value of the equity compensation was $165,000. The Company recognized an asset captioned “Deferred equity compensation” and an offsetting liability captioned as a “Liability-classified equity instrument.” During the nine months ended September 30, 2022, the Company (i) replaced certain variable share contracts with a new fixed share compensation structure and accordingly de-recognized $25,000 of deferred stock compensation and liability-classified equity instruments, and (ii) de-recognized $106,141 of deferred stock compensation and $135,000 of liability-classified equity instruments as a result of the termination of the employee and related future equity rights to which the equity asset and liability related.
Liability-classified equity instruments		90,000		$ 90,000
Deferred stock amount				7,500
Deferred stock compensation assets		1,359		$ 14,484
Common Stock [Member]
Shareholders' Equity (Details) [Line Items]
Common stock, par value (in Dollars per share)	$ 0.0001
Warrant [Member]
Shareholders' Equity (Details) [Line Items]
Issued warrants (in Shares)				3,249,244	22,421,026
Aggregate grant fair value		$ 151,909	$ 5,823,476	$ 151,909	$ 5,823,476
Issued common shares upon exercise (in Shares)			333,750		333,750
Warrants shares exercised (in Shares)			3,065,278		3,065,278
Cashless exercise (in Shares)							9,047,332
Warrant shares exercised (in Shares)							10,571,742
Litigation and other disputes amounts							$ 614,221
Minimum [Member]
Shareholders' Equity (Details) [Line Items]
Exercise price (in Dollars per share)					$ 0.1
Maximum [Member]
Shareholders' Equity (Details) [Line Items]
Exercise price (in Dollars per share)					$ 0.252
Private Placement Transaction [Member]
Shareholders' Equity (Details) [Line Items]
Proceed amount				$ 535,000	$ 4,328,725
Issuance of common stock (in Shares)				4,998,485	13,161,943
Common stock, shares issued (in Shares)		3,249,244	6,581,527	3,249,244	6,581,527
Warrant term				5 years	5 years
Private Placement Transaction [Member] | Minimum [Member]
Shareholders' Equity (Details) [Line Items]
Exercise price (in Dollars per share)		$ 0.12	$ 0.27	$ 0.12	$ 0.27
Private Placement Transaction [Member] | Maximum [Member]
Shareholders' Equity (Details) [Line Items]
Exercise price (in Dollars per share)		$ 0.25	$ 1.05	$ 0.25	1.05
Warrant [Member] | Minimum [Member]
Shareholders' Equity (Details) [Line Items]
Exercise price (in Dollars per share)					0.09
Warrant [Member] | Maximum [Member]
Shareholders' Equity (Details) [Line Items]
Exercise price (in Dollars per share)					$ 0.15
Common Stock [Member] | Employee Equity Incentives Plans [Member]
Shareholders' Equity (Details) [Line Items]
Common stock, shares issued (in Shares)									15,503,680
Employee Equity Incentives Plans [Member]
Shareholders' Equity (Details) [Line Items]
Total unrecognized compensation cost		$ 150,101		$ 150,101
Weighted-average period				2 years 2 months 12 days
Stock based compensation recognized for grants				$ 42,966	$ 64,321
Aggregate fair value of share grants		$ 388	$ 98,335	$ 388	98,335
Shares issued (in Shares)		1,394		1,394
Stock options exercised (in Shares)				12,500
Employee Stock Option [Member]
Shareholders' Equity (Details) [Line Items]
Stock based compensation recognized for grants				$ 0.12	0.27
Consultant [Member]
Shareholders' Equity (Details) [Line Items]
Recognized expenses				$ 37,696	$ 151,322
Investment Agreement [Member]
Shareholders' Equity (Details) [Line Items]
Common stock, shares issued (in Shares)			3,006,098		3,006,098
Investment Agreement [Member] | Common Stock [Member]
Shareholders' Equity (Details) [Line Items]
Net proceeds					$ 900,636

Shareholders' Equity (Details)

Shareholders' Equity (Details) - Schedule of common stock issuable - Shares issuable to consultants, employees and directors [Member] - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Shareholders' Equity (Details) - Schedule of common stock issuable [Line Items]
Common stock issuable, amount	$ 345,345	$ 282,347
Common stock issuable, shares	1,329,469	719,366

Shareholders' Equity (Details_2

Shareholders' Equity (Details) - Schedule of stock warrants - Warrant [Member] - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Shareholders' Equity (Details) - Schedule of stock warrants [Line Items]
Number of Outstanding at beginning of the period	59,796,992	51,352,986
Weighted Average Exercise Price, Outstanding at beginning of the period	$ 0.25	$ 0.17
Number of Granted during the period	3,249,244	22,421,026
Weighted Average Exercise Price, Granted during the period	$ 0.17	$ 0.39
Number of Exercised during the period		(13,637,020)
Weighted Average Exercise Price, Exercised during the period		$ (0.18)
Number of Expired during the period	(786,667)
Weighted Average Exercise Price, expired during the period	$ (0.44)
Number of Outstanding at end of the period	62,259,569	60,136,992
Weighted Average Exercise Price, Outstanding at end of the period	$ 0.24	$ 0.25
Number of Exercisable at end of the period	62,259,569	60,136,992
Weighted Average Exercise Price, Exercisable at end of the period	$ 0.24	$ 0.25
Weighted average remaining life	2 years 7 months 6 days	3 years 4 months 24 days

Shareholders' Equity (Details_3

Shareholders' Equity (Details) - Schedule of stock warrants outstanding - Warrant [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding Number Outstanding (in Shares) | shares	62,259,569
Warrants Outstanding Weighted-Average Remaining Contractual Life (years)	2 years 7 months 6 days
Warrants Outstanding Weighted-Average Exercise Price	$ 0.24
Warrants Exercisable Number Exercisable (in Shares) | shares	62,259,569
Warrants Exercisable Weighted-Average Exercise Price	$ 0.24
Minimum [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding, Exercise Prices	0.05
Maximum [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding, Exercise Prices	$ 1
Exercise Prices Two [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding Number Outstanding (in Shares) | shares	14,789,573
Warrants Outstanding Weighted-Average Remaining Contractual Life (years)	2 years 3 months 18 days
Warrants Outstanding Weighted-Average Exercise Price	$ 0.07
Warrants Exercisable Number Exercisable (in Shares) | shares	14,789,573
Warrants Exercisable Weighted-Average Exercise Price	$ 0.07
Exercise Prices Two [Member] | Minimum [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding, Exercise Prices	0.0001
Exercise Prices Two [Member] | Maximum [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding, Exercise Prices	$ 0.09
Exercise Prices Five [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding Number Outstanding (in Shares) | shares	12,690,290
Warrants Outstanding Weighted-Average Remaining Contractual Life (years)	2 years 8 months 12 days
Warrants Outstanding Weighted-Average Exercise Price	$ 0.17
Warrants Exercisable Number Exercisable (in Shares) | shares	12,690,290
Warrants Exercisable Weighted-Average Exercise Price	$ 0.17
Exercise Prices Five [Member] | Minimum [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding, Exercise Prices	0.1
Exercise Prices Five [Member] | Maximum [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding, Exercise Prices	$ 0.24
Exercise Prices Three [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding Number Outstanding (in Shares) | shares	31,319,782
Warrants Outstanding Weighted-Average Remaining Contractual Life (years)	2 years 7 months 6 days
Warrants Outstanding Weighted-Average Exercise Price	$ 0.31
Warrants Exercisable Number Exercisable (in Shares) | shares	31,319,782
Warrants Exercisable Weighted-Average Exercise Price	$ 0.31
Exercise Prices Three [Member] | Minimum [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding, Exercise Prices	0.25
Exercise Prices Three [Member] | Maximum [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding, Exercise Prices	$ 0.49
Exercise Prices Four [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding Number Outstanding (in Shares) | shares	3,459,924
Warrants Outstanding Weighted-Average Remaining Contractual Life (years)	3 years 9 months 18 days
Warrants Outstanding Weighted-Average Exercise Price	$ 0.69
Warrants Exercisable Number Exercisable (in Shares) | shares	3,459,924
Warrants Exercisable Weighted-Average Exercise Price	$ 0.69
Exercise Prices Four [Member] | Minimum [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding, Exercise Prices	0.5
Exercise Prices Four [Member] | Maximum [Member]
Shareholders' Equity (Details) - Schedule of stock warrants outstanding [Line Items]
Warrants Outstanding, Exercise Prices	$ 1.05

Shareholders' Equity (Details_4

Shareholders' Equity (Details) - Schedule of fair value of the warrants - Warrant [Member]	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Shareholders' Equity (Details) - Schedule of fair value of the warrants [Line Items]
Pricing model utilized	Binomial Lattice	Binomial Lattice
Risk free rate range	2.94%
Expected life range (in years)	5 years
Volatility range	74.50%
Dividend yield	0%	0%
Minimum [Member]
Shareholders' Equity (Details) - Schedule of fair value of the warrants [Line Items]
Risk free rate range		0.38%
Expected life range (in years)		3 years
Volatility range		170.58%
Maximum [Member]
Shareholders' Equity (Details) - Schedule of fair value of the warrants [Line Items]
Risk free rate range		0.97%
Expected life range (in years)		5 years
Volatility range		193.21%

Shareholders' Equity (Details_5

Shareholders' Equity (Details) - Schedule of financial statements with respect to the EIPs - Employee Equity Incentives Plans [Member] - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Class of Warrant or Right [Line Items]
Total cost of share-based payment plans during the period	$ 335,860	$ 574,998
Amounts capitalized in deferred equity compensation during period
Amounts charged against income for amounts previously capitalized	(9,375)
Amounts charged against income, before income tax benefit	326,485	574,998
Amount of related income tax benefit recognized in income

Shareholders' Equity (Details_6

Shareholders' Equity (Details) - Schedule of stock option activity - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Schedule of Stock Option Activity [Abstract]
Outstanding at beginning of period, shares	3,456,250	3,111,750
Weighted Average Exercise Price, Outstanding at beginning of period	$ 0.23	$ 0.2
Granted during the period, shares	975,000	80,000
Weighted Average Exercise Price, Granted during the period	$ 0.16	$ 0.75
Exercised during the period, shares	(12,500)	(145,500)
Weighted Average Exercise Price, Exercised during the period	$ (0.26)	$ (0.11)
Forfeited during the period, shares	(419,500)	(32,500)
Weighted Average Exercise Price, Forfeited during the period	$ (0.31)	$ (0.16)
Outstanding at end of the period, shares	3,999,250	3,013,750
Weighted Average Exercise Price, Outstanding at end of the period	$ 0.2	$ 0.22
Options exercisable at period-end, shares	2,655,500	2,173,750
Weighted Average Exercise Price, Options exercisable at period-end	$ 0.2	$ 0.19

Shareholders' Equity (Details_7

Shareholders' Equity (Details) - Schedule of fair value of options granted	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Shareholders' Equity (Details) - Schedule of fair value of options granted [Line Items]
Pricing model utilized	Binomial Lattice	Binomial Lattice
Expected life range (in years)	10 years	10 years
Dividend yield	0%	0%
Minimum [Member]
Shareholders' Equity (Details) - Schedule of fair value of options granted [Line Items]
Risk free rate range	2.81%	1.47%
Volatility range	74.38%	74.38%
Maximum [Member]
Shareholders' Equity (Details) - Schedule of fair value of options granted [Line Items]
Risk free rate range	2.90%	2.90%
Volatility range	74.50%	192.25%

Shareholders' Equity (Details_8

Shareholders' Equity (Details) - Schedule of non-vested options issued - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Schedule of Non Vested Options Issued [Abstract]
Nonvested at beginning of period, shares	858,750	1,044,375
Weighted Average Grant Date Fair Value, Nonvested at beginning of period	$ 0.23	$ 0.21
Granted, shares	975,000	80,000
Weighted Average Grant Date Fair Value, Granted	$ 0.09	$ 0.62
Vested, shares	(195,750)	(255,000)
Weighted Average Grant Date Fair Value, Vested	$ (0.22)	$ (0.25)
Forfeited, shares	(294,250)	(29,375)
Weighted Average Grant Date Fair Value, Forfeited	$ (0.26)	$ (0.12)
Nonvested at end of period, shares	1,343,750	840,000
Weighted Average Grant Date Fair Value, Nonvested at end of period	$ 0.12	$ 0.24

Shareholders' Equity (Details_9

Shareholders' Equity (Details) - Schedule of stock grant activity - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Schedule of Stock Grant Activity [Abstract]
Nonvested grants at beginning of period, Shares	302,050	200,000
Nonvested grants at beginning of period, Weighted average grant date fair value	$ 0.27	$ 0.17
Granted, Shares	377,454	1,015,047
Granted, Weighted average grant date fair value	$ 0.17	$ 0.27
Vested Shares	(354,782)	(1,075,047)
Vested Weighted average grant date fair value	$ (0.23)	$ (0.26)
Forfeited Shares	(104,954)	(50,000)
Forfeited Weighted average grant date fair value	$ (0.19)	$ (0.1)
Nonvested at end of period Shares	219,768	90,000
Nonvested at end of period Weighted average grant date fair value	$ 0.2	$ 0.19

Contingent Acquisition Consid_3

Contingent Acquisition Consideration (Details) - USD ($)		1 Months Ended						9 Months Ended	12 Months Ended
	Apr. 12, 2019	May 31, 2022	Sep. 30, 2021	May 31, 2021	Oct. 19, 2020	May 31, 2020	May 18, 2020	Sep. 30, 2022	May 18, 2021	Jul. 19, 2022
Contingent Acquisition Consideration (Details) [Line Items]
Cash paid								$ 158,160		$ 561,000
Plan Year 2020 [Member]
Contingent Acquisition Consideration (Details) [Line Items]
Amount of medicare shared savings and received payment			$ 2,419,312
Hughes Center for Functional Medicine Acquisition [Member]
Contingent Acquisition Consideration (Details) [Line Items]
Acquired interest	100%
Cash paid	$ 500,000
Earn-out amount	500,000
Fair value transaction	$ 1,764,672
Paid to sellers		$ 207,384		$ 196,000		$ 47,000
Hughes Center for Functional Medicine Acquisition [Member] | Common Stock [Member]
Contingent Acquisition Consideration (Details) [Line Items]
Share issued (in Shares)	3,968,254
Cura Health Management LLC Acquisition [Member]
Contingent Acquisition Consideration (Details) [Line Items]
Acquired interest							100%
Earn-out amount			366,300						$ 62,500
Paid to sellers			124,043
Terms of acquisition, description								Following the acquisition and through third quarter 2022, the business of CHM comprised the Company’s ACO/MSO Division. Under the terms of acquisition, the Company paid CHM shareholders the following consideration: (i) $214,000 in cash paid at closing, (ii) 2,240,838 shares of the Company’s common stock issued at closing, (iii) up to $223,500 additional cash and $660,000 in additional shares of the Company’s common stock payable at the time CHM receives the final assessment of the calculation of MSSP savings for the 2019 program year, with this amount prorated based on a target MSSP payment (plus other ancillary revenue) of $1,725,000, and (iv) up to $437,500 based on the business achieving annual revenue of $2,250,000 and annual profit of $500,000 in each of the four years following closing.
Terms of earn out, description								The terms of the earn out required the Company to pay the former owners of CHM (i) up to $223,500 additional cash and to $660,000 of additional shares of Company common stock when CHM receives the final assessment of the calculation of 2019 plan year MSSP revenue (the “Current Earnout”), and (ii) up to $62,500, $125,000, $125,000 and $125,000 on the first, second, third and fourth anniversary, respectively, based on achievement by the underlying business of revenue of at least $2,250,000 (50% weighting) and profit of at least $500,000 (50% weighting) in the year preceding each anniversary date (the “Future Earnout”). During September 2020, pursuant to a Second Amendment to the Agreement and Plan of Merger (the “Second Amendment”) and in satisfaction of the Current Earnout, the Company paid $90,389 cash, issued 1,835,625 shares of the Company’s common stock and agreed that the balance of the Current Earnout that was not earned in 2020, being $124,043 cash and $366,300 in shares of Company common stock, would be deferred until the first future earnout year in which MSSP revenue exceeds $1.725 million and revenue from other services exceeds $605,000 (the “Residual Earnout”).
Saving payment exceeded			$ 1,725,000
Cura Health Management LLC Acquisition [Member] | Common Stock [Member]
Contingent Acquisition Consideration (Details) [Line Items]
Share issued (in Shares)			806,828
MedOffice Direct LLC Acquisition [Member]
Contingent Acquisition Consideration (Details) [Line Items]
Acquired interest					100%
Terms of acquisition, description					the Company acquired a 100% interest in MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States. With over 13,000 name brand medical products in over 150 different categories, MOD leverages pricing discounts with a small unit-of-measure direct-to-consumer shipping model to make ordering medical supplies more convenient and cost effective for its users. The Company accounted for the transaction as an acquisition of a business pursuant to ASC 805. Following the acquisition, the business of MOD comprised the Company’s Medical Distribution Division. Under the terms of acquisition, the Company paid the following consideration: (i) 19,045,563 shares of Company common stock issued at closing, (ii) partial satisfaction of certain outstanding debt obligations of MOD in the amount of $703,200 in cash paid by the Company, and (iii) up to 10,004,749 restricted shares of the Company’s common stock over a four-year period based on MOD achieving revenue targets in calendar years 2021 through 2024 of $1,500,000, $1,875,000, $2,344,000, and $2,930,000, respectively.

Contingent Acquisition Consid_4

Contingent Acquisition Consideration (Details) - Schedule of fair value of contingent acquisition - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Contingent Acquisition Consideration (Details) - Schedule of fair value of contingent acquisition [Line Items]
Total contingent acquisition consideration	$ 312,733	$ 1,185,690
Less: long term portion	(184,659)	(782,224)
Contingent acquisition consideration, current portion	128,074	403,466
Fair value of HCFM contingent acquisition consideration [Member]
Contingent Acquisition Consideration (Details) - Schedule of fair value of contingent acquisition [Line Items]
Total contingent acquisition consideration		172,124
Fair value of CHM contingent acquisition consideration [Member]
Contingent Acquisition Consideration (Details) - Schedule of fair value of contingent acquisition [Line Items]
Total contingent acquisition consideration	218,236	276,529
Fair value of MOD contingent acquisition consideration [Member]
Contingent Acquisition Consideration (Details) - Schedule of fair value of contingent acquisition [Line Items]
Total contingent acquisition consideration	$ 94,497	$ 737,037

Contingent Acquisition Consid_5

Contingent Acquisition Consideration (Details) - Schedule of gains (losses) on the change in the fair value of contingent acquisition - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Business Acquisition, Contingent Consideration [Line Items]
Total change in fair value of contingent acquisition consideration	$ 133,483	$ 126,411	$ 665,573	$ (234,678)
Change in fair value of HCFM contingent acquisition consideration [Member]
Business Acquisition, Contingent Consideration [Line Items]
Total change in fair value of contingent acquisition consideration		(14,316)	(35,259)	(63,769)
Change in fair value of CHM contingent acquisition consideration [Member]
Business Acquisition, Contingent Consideration [Line Items]
Total change in fair value of contingent acquisition consideration	62,516	(116,150)	58,292	(54,848)
Change in fair value of MOD contingent acquisition consideration [Member]
Business Acquisition, Contingent Consideration [Line Items]
Total change in fair value of contingent acquisition consideration	$ 70,967	$ 256,877	$ 642,540	$ (116,061)

Contingent Acquisition Consid_6

Contingent Acquisition Consideration (Details) - Schedule of maturities of contingent acquisition consideration	9 Months Ended
	Sep. 30, 2022 USD ($)
Schedule of Maturities of Contingent Acquisition Consideration [Abstract]
2022 (October to December)	$ 92,546
2023	85,169
2024	135,018
Total	$ 312,733

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)					9 Months Ended
	Jul. 01, 2025	Jul. 01, 2024	Jul. 01, 2023	Oct. 13, 2022	Sep. 30, 2022	Sep. 30, 2021
Commitments and Contingencies (Details) [Line Items]
Supplier percentage					96%
Cash payment, description				The Agreement was effective as of July 1, 2022 and provides that Mr. O’Leary’s base salary will be $259,000 per year, with annual review and adjustment at the discretion of the Chief Executive Officer and Compensation Committee of the Board of Directors of the Company, and an annual incentive bonus of 25% of annual salary based on the achievement of the Company of certain financial metrics as approved by the Compensation Committee.
Cash bonus (in Dollars)					$ 50,000
Grants restricted shares					100,000
Granted stock option					377,454	1,015,047
Stock options exercise price (in Dollars per share)					$ 0.16	$ 0.75
Forecast [Member]
Commitments and Contingencies (Details) [Line Items]
Grants restricted shares	100,000	100,000	100,000
Mr. O’Leary [Member]
Commitments and Contingencies (Details) [Line Items]
Granted stock option					1,200,000
Stock options exercise price (in Dollars per share)					$ 0.06

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of maturities of operating lease liabilities - Operating Leases [Member]	Sep. 30, 2022 USD ($)
Commitments and Contingencies (Details) - Schedule of maturities of operating lease liabilities [Line Items]
2022 (October to December)	$ 119,116
2023	396,833
2024	126,116
2025	74,729
2026	18,148
2027	990
Total lease payments	735,932
Less interest	(97,328)
Present value of lease liabilities	$ 638,604

Segment Reporting (Details)

Segment Reporting (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Segment Reporting (Details) [Line Items]
Number of reportable segments			4
Subscription revenue billed and paid	$ 180	$ 400	$ 640	$ 743
Medical Distribution Segment [Member]
Segment Reporting (Details) [Line Items]
Subscription revenue billed and paid	$ 3,144	$ 0	$ 25,214	$ 9

Segment Reporting (Details) - S

Segment Reporting (Details) - Schedule of segment information - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Health Services [Member]
Revenue
Patient service revenue, net	$ 1,262,253	$ 1,394,356	$ 4,069,714	$ 4,379,282
Subscription, consulting and event revenue
Product revenue
Total revenue	1,262,253	1,394,356	4,069,714	4,379,282
Operating Expenses
Practice salaries and benefits	810,058	739,024	2,344,529	2,305,993
Other practice operating expenses	695,300	549,086	1,897,070	1,790,874
Medicare shared savings expenses
Cost of product revenue
Selling, general and administrative expenses
Depreciation and amortization	31,198	26,196	87,134	83,493
Total Operating Expenses	1,536,556	1,314,306	4,328,733	4,180,360
Loss from operations		80,050
Income from operations	(274,303)		(259,019)	198,922
Other Segment Information
(Gain) loss on extinguishment of debt				(502,959)
Change in fair value of debt
Other Segment Information
Identifiable assets	2,182,272	2,104,819	2,182,272	2,104,819	$ 2,152,533
Goodwill	319,958		319,958
Other Segment Information
Interest expense	2,815	2,706	8,420	5,145
Financing cost	110,000		110,000
Amortization of original issue discounts on notes payable	18,480		18,480
Change in fair value of contingent acquisition consideration
Digital Healthcare [Member]
Revenue
Patient service revenue, net
Subscription, consulting and event revenue	1,171		9,433	11,905
Product revenue
Total revenue	1,171		9,433	11,905
Operating Expenses
Practice salaries and benefits
Other practice operating expenses
Medicare shared savings expenses
Cost of product revenue
Selling, general and administrative expenses	1,055,178	1,093,461	3,529,289	3,472,493
Depreciation and amortization	1,406	2,215	4,472	3,405
Total Operating Expenses	1,056,584	1,095,676	3,533,761	3,475,898
Loss from operations		(1,095,676)
Income from operations	(1,055,413)		(3,524,328)	(3,463,993)
Other Segment Information
(Gain) loss on extinguishment of debt				5,471,884
Change in fair value of debt				19,246
Other Segment Information
Identifiable assets	507,030	3,967,850	507,030	3,967,850	3,450,332
Goodwill
Other Segment Information
Interest expense	2,825	1,412	6,731	8,038
Amortization of original issue discounts on notes payable	2,540		2,540
Change in fair value of contingent acquisition consideration	(133,483)	(126,411)	(665,573)	234,678
ACO / MSO [Member]
Revenue
Patient service revenue, net
Medicare shared savings revenue		2,419,312		2,419,312
Subscription, consulting and event revenue	88,806	69,595	251,058	217,209
Product revenue
Total revenue	88,806	2,488,907	251,058	2,636,521
Operating Expenses
Practice salaries and benefits
Other practice operating expenses
Medicare shared savings expenses	337,533	1,748,585	802,411	2,157,555
Cost of product revenue
Selling, general and administrative expenses
Depreciation and amortization
Total Operating Expenses	337,533	1,748,585	802,411	2,157,555
Loss from operations		740,322
Income from operations	(248,727)		(551,353)	478,966
Other Segment Information
(Gain) loss on extinguishment of debt
Change in fair value of debt
Other Segment Information
Identifiable assets	1,132,696	2,850,949	1,132,696	2,850,949	1,167,965
Goodwill	381,856	381,856	381,856	381,856	381,856
Other Segment Information
Interest expense
Change in fair value of contingent acquisition consideration
Medical Distribution [Member]
Revenue
Patient service revenue, net
Subscription, consulting and event revenue
Product revenue	95,449	161,456	372,877	512,325
Total revenue	95,449	161,456	372,877	512,325
Operating Expenses
Practice salaries and benefits
Other practice operating expenses
Medicare shared savings expenses
Cost of product revenue	87,775	145,432	419,129	474,026
Selling, general and administrative expenses	32,955	54,130	149,495	188,713
Depreciation and amortization	176,900	176,900	530,700	536,540
Total Operating Expenses	297,630	376,462	1,099,324	1,199,279
Loss from operations		(215,006)
Income from operations	(202,181)		(726,447)	(686,954)
Other Segment Information
(Gain) loss on extinguishment of debt				(11,757)
Change in fair value of debt
Other Segment Information
Identifiable assets	2,188,509	2,890,389	2,188,509	2,890,389	2,775,621
Goodwill	766,249	766,249	766,249	766,249	766,249
Other Segment Information
Interest expense				(100)
Change in fair value of contingent acquisition consideration
Total [Member]
Revenue
Patient service revenue, net	1,262,253	1,394,356	4,069,714	4,379,282
Medicare shared savings revenue		2,419,312		2,419,312
Subscription, consulting and event revenue	89,977	69,595	260,491	229,114
Product revenue	95,449	161,456	372,877	512,325
Total revenue	1,447,679	4,044,719	4,703,082	7,540,033
Operating Expenses
Practice salaries and benefits	810,058	739,024	2,344,529	2,305,993
Other practice operating expenses	695,300	549,086	1,897,070	1,790,874
Medicare shared savings expenses	337,533	1,748,585	802,411	2,157,555
Cost of product revenue	87,775	145,432	419,129	474,026
Selling, general and administrative expenses	1,088,133	1,147,591	3,678,784	3,661,206
Depreciation and amortization	209,504	205,311	622,306	623,438
Total Operating Expenses	3,228,303	4,535,029	9,764,229	11,013,092
Loss from operations		(490,310)
Income from operations	(1,780,624)		(5,061,147)	(3,473,059)
Other Segment Information
(Gain) loss on extinguishment of debt				4,957,168
Change in fair value of debt				19,246
Other Segment Information
Identifiable assets	6,010,507	11,814,007	6,010,507	11,814,007	9,546,451
Goodwill	1,468,063	1,148,105	1,468,063	1,148,105	$ 1,148,105
Other Segment Information
Interest expense	5,640	4,118	15,151	13,083
Financing cost	110,000		110,000
Amortization of original issue discounts on notes payable	21,020		21,020
Change in fair value of contingent acquisition consideration	$ (133,483)	$ (126,411)	$ (665,573)	$ 234,678

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - Schedule of fair value measurements - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 395,858	$ 1,348,190
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	395,858	1,348,190
Liability-classified equity instruments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	83,125	162,500
Liability-classified equity instruments [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Liability-classified equity instruments [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Liability-classified equity instruments [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	83,125	162,500
Contingent acquisition consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	312,733	1,185,690
Contingent acquisition consideration [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Contingent acquisition consideration [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Contingent acquisition consideration [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 312,733	$ 1,185,690

Fair Value of Financial Instr_4

Fair Value of Financial Instruments (Details) - Schedule of level 3 financial instruments measured at fair value on recurring basis - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total	$ 133,483	$ 126,411	$ 665,573	$ (253,924)
Convertible notes payable [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total				(19,246)
Contingent acquisition consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total	$ 133,483	$ 126,411	$ 665,573	$ (234,678)

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)				9 Months Ended
	Nov. 08, 2022	Oct. 21, 2022	Oct. 13, 2022	Sep. 30, 2022	Sep. 30, 2021
Subsequent Events (Details) [Line Items]
Subsequent event, description				The Agreement also provides that Mr. O’Leary will receive a grant of 100,000 shares of restricted stock upon execution of the Agreement and additional grants of 100,000 restricted shares on each of July 1, 2023, 2024 and 2025.
Exercise price (in Dollars per share)				$ 0.09	$ 0.62
Principal amount		$ 144,760
Original issue discount amount		15,510
Original issue discount fees		4,250
Net proceeds		125,000
Required monthly payment amount		$ 16,213
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Advance received	$ 150,000
Notes payables	$ 3,750
Chief Financial Officer [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
base salary			$ 259,000
Chief Executive Officer [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Incentive bonus percentage			25%
Mr. O’Leary [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Cash bonus			$ 50,000
Stock option (in Shares)			1,200,000
Exercise price (in Dollars per share)			$ 0.06